||DL-AP4 is a Broad spectrum EAA antagonist.
||Substance P free acid
||Substance P free acid is a Sensory neuropeptide and inflammatory mediator. Exerts excitatory effects on central and peripheral neurons, constricts bronchioles and is involved in pain transmission.
||AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Ki =12 nM and 4,200 nM for CB1 and CB2, respectively).
||Sarecycline, also known as P005672, is a novel, tetracycline-derived, narrow-spectrum antibiotic being developed for use as an oral once daily antibiotic treatment for patients suffering from moderate to severe acne vulgaris.
||SU 5214 is a modulator of tyrosine kinase signal transduction.
||GS-441524 inhibits replication of serotype II FIP virus (FIPV) in CRFK cell cultures with EC50 of ~1 uM.
||Azimilide(NE-10064) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
||Cambendazol is an antihelmintic that, at a dose of 50 mg/kg/day in mice, eradicates S. ratti adult worms from intestine and S. stercoralis larva from muscle.
||Methylphenidate hydrochloride is a central nervous system stimulant
||Losartan Carboxylic Acid
||Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.
||HBX 41108 is an inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM).
||SRT3025 is a sirt1 activator.
||Tazarotenic acid, an active metabolite of tazarotene, is a potent and selective agonist of the retinoid receptor (RAR) that binds to RARα, RARβ, and RARγ.
||Etelcalcetide (AMG 416) is a novel, long-acting selective peptide agonist of the calcium sensing receptor, activates calcium sensing receptor on parathyroid glands reducing PTH synthesis and secretion.
||RN-1 (hydrochloride) is a potent and irreversible LSD1 inhibitor with IC50 values of 10-70 nM. However, RN-1 is much less effective against MAO-A and MAO-B with IC50 values of 0.51 and 2.785 μM
||PBIT is a potent, cell-permeable inhibitor of Jumonji histone demethylase (JHDM). Innhibits JARID1B (also known as KDM5B or PLU1) with an IC50 of about 3 μm in vitro.
||Ximelagatran is an orally active direct thrombin inhibitor.
||PS47 has a E-configuration in comparison with its active Z-isomer PS48.
||LHW090-A7 is a potential inhibitor of neutral endopeptidase (NEP).
||Auten-99 is a novel inhibitor of the myotubularin phosphatase Jumpy (also called MTMR14), acrossing the blood-brain barrier and exerting potent neuroprotective effects.
||Beta-guanidinopropionic acid is a novel creatine kinase inhibitor.
||DNQX is a AMPA receptor antagonists.
||1-EBIO is an Epithelial KCa channel activator.
||RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. RGX-104 depletes myeloid derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs), activating cytotoxic lymphocytes (CTLs) with anti-tumor activity.
||Gefapixant(AF-219,MK-7264) is novel P2X3 receptor antagonist.
||D-Lin-MC3-DMA(MC3) is the most potent cationic lipid that has been synthesized for Lipid nanoparticles (LNPs) to deliver the siRNA.
||NAV-2729 is a dual Arf1/Arf6 activation inhibitor.
||KHS101 is primarily found to selectively induce a neuronal differentiation phenotype by interaction with TACC3 protein, with the ability to cross the blood-brain barrier. KHS101 is recently found to promote tumor cell death in diverse glioblastoma multiforme (GBM) cell models, independent of their tumor subtype, and without affecting the viability of noncancerous brain cell lines.
||(-)-CXL017 is a small molecule that has selective cytotoxicity toward MDR cancer cell lines in vitro, through inhibition of the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) with IC50 of 13.5 uM.
||(5Z)-7-Oxozeaenol is a potent and selective TAK1 inhibitor with IC50 of 8 nM, displays >33-fold and >62-fold selectivity over MEKK1 and MEKK4 respectively.
||the R-enantiomer of the nootropic drug oxiracetam (ISF 2522), which is a nootropic drug of the racetam family and stimulant..
||RTS-V5 is the first-in-class dual histone deacetylase-proteasome inhibitor with IC50 of 0.27 µM for HDAC6 and blocks the chymotrypsin-like proteasome activity.
||PC786 is a potent and selective inhibitor of RSV RNA-dependent RNA polymerase (RdRp).
||DS-8500a is a novel, orally available, selective GPR119 agonist and increases intracellular cAMP in human, rat, and mouse GPR119 expressing CHO-K1 cells with EC50 of 51.5 nM, 98.4 nM and 108.1 nM, respectively.
||GSK2646264 is a potent and selective spleen tyrosine kinase inhibitor with pIC50 of 7.1 and demonstrates good selectivity (at least 30-fold) against the other kinases (Aurora A, Aurora B, VEGFR2, JAK2, GSK3β, LCK and LRRK2)
||NYX-2925 is a non-opioid, selective, and central-acting NMDAR modulator.
||AZD3229 is a potent pan-Kit mutant inhibitor and demonstrates potent single digit nM growth inhibition across a broad cell panel, with good margin to KDR-driven effects.
||TUG-1375 is a potent thiazolidine free fatty acid receptor 2 agonist with pKi of 6.69.
||LY3298176 is a novel dual GIP and GLP-1 receptor agonist with Ki of 0.135 and 4.23, respectively.
||GSK852A is a NS5B inhibitor.
||GSK8175 is a NS5B inhibitor.
||TT-10 is a novel multifaceted fluorinated compound, which increases cardiomyocytes and protect the heart after ischemic injury.
||Active triphosphate metabolite of GS-441524, which inhibits replication of serotype II FIP virus (FIPV) in CRFK cell cultures with EC50 of ~1 uM.
||NVR 3-778 is the first capsid assembly modulator (CAM) that inhibits viral replication (rcDNA formation) and the production of secreted HBV DNA virions in HepG2.2.15 cells with EC50 of 0.34 µM and 0.40 µM, respectively.
||Compound 8 (ZINC05007751) is a novel inhibitor of the NIMA-related kinase with IC50 of 3.4 µM.
||XL-13m is an ENL YEATS-selective inhibitor with IC50 of 0.56 μM.
||VU0424238 (Auglurant) is a novel negative allosteric modulator of mGlu5 with Ki of 4.4 nM, which is more than 900-fold selectivity versus the other mGlu receptors.
||VU0652835 is a potent negative allosteric modulator of mGlu5 with excellent CNS penetration.
||PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC,, which degrades BCL6 across a number of DLBCL cell lines via the expected ubiquitin-proteasome mediated pathway.
||HMG499 (HMGCR degrader Cmpd 81) is a potent HMG-CoA reductase degrader with EC50 of 0.41μM.
||PF-06305591 is a potent highly selective NaV1.8 blocker with IC50 of 15 nM.
||MDI-2268 is noval oral inhibitor of a plasminogen-activator inhibitor type-1 (PAI-1).
||COH000 is a highly specific covalent allosteric inhibitor of SUMO E1.
||TD-0212 is an orally active, dual AT1 antagonist/NEP inhibitor (ARNI) with pKi and pIC50 of 8.9 and 9.2, respectively.
||Epetraborole hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding "to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase".
||GBT 440 is a modulator of sickle hemoglobin (HbS), extracted from patent WO2015116061A1, compound 5, which can be used in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
||NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 2.5 µM.
||WNK463 is an orally bioavailable pan-WNK-kinase inhibitor.
||AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.
||PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.
||Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively.
||Alsterpaullone is a potent ATP-competitive and cell cycle cyclin-dependent kinase inhibitor, that is reported to be the most active Paullone.
||3-Cyano-7-ethoxycoumarin is a fluorogenic cytochrome P-450 substrate that generates blue fluorescent product upon enzyme cleavage Target.
||GSK-8573(negative control of GSK-2801)
||GSK-8573 is the inactive control of GSK-2801.
||CPI-169(R), EZH2 Inhibitor
||CPI-169 is a novel and potent EZH2 inhibitor, with IC50s of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
||RSL3 1S, 3R-
||RSL3 is the inhibitor of the glutathione (GSH) peroxidase 4, which can inhibit the cysteine/glutamate amino acid transporter system that blocks GSH synthesis with an IC50 of 100 nM.
||RK-33 is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.
||Indirubin (Couroupitine B)
||Indirubin(Couroupitine B) is a purple 3,2- bisindole and a stable isomer of indigo isolated from Indigo naturalis (Apiaceae); anti-inflammatory and anticancer activities.
||StemRegenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with IC50 of 127 nM.
||PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) and inhibits PFKFB3 activity in cancer cells with IC50 of 20 nM.
||TH-302 is a hypoxia-activated prodrug with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively.
||PBTZ169 is a new drug candicate that inhibits decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1), more efficiently than BTZ043
In vitro: PBTZ169, inhibit decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1) and display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
||Glutaminase C-IN-1 (968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.
||Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger.
||SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM.
||Ezutromid is a novel Small utrophin's translation modulator with EC50 of 0.4 uM .
||Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.
||LTI-291 is an activator of glucocerebrosidase (Gcase) extracted from patent WO 2017192841 A1.
||GJ103 sodium salt
||GJ103 sodium salt is an active analog of the read-through compound GJ072.
||Mad2 inhibitor-1 (M2I-1)
||M2I-1 a small Mad2 inhibitor-1.
||1-methyl-7-nitroisatoic anhydride is a reagent that detects local nucleotide flexibility, for probing 2'-hydroxyl reactivity.
||Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
||GKT137831 is a novel, specific dual NADPH oxidase (NOX1/4) inhibitor. GKT137831 has potency both on human Nox4 (Ki=140±40 nM) and human Nox1 (Ki=110±30 nM) and is found 15-fold less potent on Nox2 (Ki=1750±700 nM) and 3-fold less potent on Nox5 (Ki=410±100 nM).
||J-147 is a broad spectrum neuroprotective phenyl hydrazide compound(EC50=60-115 nM) with significant neurotrophic properties related to the induction of brain-derived neurotrophic factor (BDNF).
||ISX-9 is a small molecule inducer of adult neural stem cell differentiation.
||Bindarit(AF-2838), a CCL2, CCL7 and CCL8 inhibitor, is an anti-inflammatory agent.
||BVT 2733 is a new, small molecule, non-steroidal, isoform-selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
||Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
||Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human.
||Teriflunomide is the active metabolite of leflunomide, which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase, used as an immunomodulatory agent.
||Genistin is the major isoflavonoid of soybeans and soy products.
||Tirasemtiv is an activator of the fast skeletal muscle troponin complex.
||Lycopene is naturally occurring carotenoids found in tomato, tomato products, and in other red fruits and vegetables; exhibits antioxidant effects.
||RG3039 (PF-06687859) is an orally bioavailable and brain-penetrant DcpS inhibitor with an IC50 of 0.069 nM.
||TPT-260(TPU260) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this molecule as TPT-260.
||CH-223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor.
||Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
||Beta-N-methylamino-L-alanine (L-BMAA) is a potent agonist of 'metabolotropic' glutamate receptors.
||Proteinase K is used to digest protein and remove contamination from preparations of nucleic acid.
||Ciraparantag(PER977) is an intravenously administered anticoagulant Reversal Agent.
||ASP 7663 is a selective TRPA1 activator (EC50 values are ~0.5 μM in human, mouse and rat).
||SB 9200 is a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
||Inarigivir (ORI-9020, SB-9000)
||Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce extracellular (virion) HBV DNA levels with EC50 of 1.2 μM.
||3PO is a novel small-molecule inhibitor of the PFKFB3 isozyme, 3PO markedly attenuates the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50, 1.4-24 μM).
||Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.
||4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.
||Glycyrrhizic acid is a triterpenoid saponinl, extracted from the licorice root, with anti-tumor, anti-diabetic activities.
||Mycophenolate Mofetil(RS 61443) is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively.
||Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug.
||Mirin is a small-molecule inhibitor of MRN (Mre11, Rad50, and Nbs1) complex.
||L-Ascorbic acid sodium
||L-Ascorbic acid (sodium) is a more bioavailable form of vitamin C that is an antioxidant agent.
||Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor.
||Chlormethine hydrochloride is a vesicant and necrotizing irritant destructive to mucous membranes. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas.
||Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.
||Astragaloside A is one of the major active constituents of Astragalus membranaceus in Traditional Chinese Medicine; has been widely used to treat ischemic diseases.
||Gimeracil(Gimestat) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination.
||INH1 is a small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.
||Alendronate sodium hydrate (MK 217)
||Alendronate (sodium hydrate) is a farnesyl diphosphate synthase inhibitor with IC50 of 460 nM.
||Aloin(Aloin-A; Barbaloin-A) is a natural antitumor anthraquinone glycoside with iron chelating and non-atherogenic activities.
||CCF642 is a novel PDI-inhibiting compound with antimyeloma activity.
||Coumarin is the primary bioactive ingredient in Radix Glehniae, named Beishashen in China, which possesses many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.
||2-mercaptoethane sulfonate (Mesna), is a synthetic small molecule, widely used as a systemic protective agent against chemotherapy toxicity, but is primarily used to reduce hemorrhagic cystitis induced by cyclophosphamide.
||(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.
||Amygdalin is a plant glucoside isolated from the stones of rosaceous fruits, such as apricots, peaches, almond, cherries, and plums.
||10-Deacetylbaccatin-III is an intermediate for taxol analog preparations.
||INH6 is a potent Nek2/Hec1 inhibitor; inhibits the growth of HeLa cells with an IC50 of 2.4 μM.
||Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.
||Methyl-β-cyclodextrin, a cyclic heptasaccharide, is an effective agent for the depletion of cholesterol from cells; also inhibits PEL cell growth with an IC50 of 3.33-4.23 mM.
||Pimelic Diphenylamide 106 analog
||Pimelic Diphenylamide 106 analog is an analog of Pimelic Diphenylamide 106 with unknown biological activity.
||N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-l/PD-Ll interaction, mainly used for cancer treatment.
||NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.
||MUC5AC motif peptide
||MUC5AC motif peptide is a 16-amino acid fragment of mucin 5.
||SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine)
||rGHRH(1-29)NH2 is a synthetic peptide which can stimulate the growth hormone (GH) secretion.
||GK921 is a transglutaminase 2 (TGase) inhibitor with an IC50 of 7.71 μM for human recombinant TGase 2.
||3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative with antitumor activity.
||Vapreotide, a synthetic analog of somatostatin, has NK1R antagonist activity.
||ABL127 is a selective and covalent inhibitor of protein methylesterase 1 (PME-1) with IC50s of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.
||A802715 is a methylxanthine derivative. A802715 has a TD50 (toxic dose of 50%) of 0.9-1.1 mM.
||Vitamin CK3 is the combination of Vitamin C and vitamin K3 and has been shown to inhibit tumor growth and lung metastasis.
||Cinobufotalin is one of the bufadienolides prepared from toad venom; has anticancer activity.
||ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.
||Amcasertib is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.
||Exherin trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
||Urolithin A is an intestinal metabolite of ellagic acid with antioxidant and antiproliferative effects; inhibits T24 and Caco-2 cell growth with IC50 values of 43.9 and 49 μM, respectively.
||Tubeimoside II(Tubeimoside-B) is a natural analogue of oleanane type of triterpenoid saponin; show anti-inflammatory, antitumor, and antitumor-promoting effects.
||Carglumic acid, a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
||Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH is a drug for cancer.
||TCV-309 (chloride) is a platelet activating factor (PAF) antagonist.
||DMCM (hydrochloride) is Benzodiazepine inverse agonist that displays anxiogenic and potent convulsant activity.
||STK16-IN-1 is a STK16 kinase inhibitor with an IC50 of 295 nM.
||4,4'-Dimethoxybenzil is a human intestinal carboxyl esterase (hiCE) inhibitor with Ki of 70 nM.
||Nesiritide is a endogenous peptide secreted from cardiac ventricles in response to volume increase and pressure overload that acts as an agonist at atrial natriuretic peptide (ANP) receptor A (NRP1).
||Oxyphenisatine (Oxyphenisatin) is a laxative. Oxyphenisatin acetate is the pro-drug of oxyphenisatin with anticancer activity.
||Fatostatin A is a inhibitor of SREBP that directly binds SCAP and blocks its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells.
||Retinyl acetate is a natural form of vitamin A and has potential antineoplastic and chemo preventive activities.
||Noscapine is an orally administrable drug used worldwide for cough suppression, primarily mediated by its σ-receptor agonist activity, and possess anticancer activity.
||TNP-470 is a methionine aminopeptidase-2 inhibitor and also an angiogenesis inhibitor.
||GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM in an assay detecting released CoA.
||LTX-315 is an oncolytic peptide with potent anticancer activity; inhibits MRC-5, A20 and AT84 with IC50s of 34.3, 8.3 and 11 µM, respectively.
||RR6 is a selective, reversible, and competitive vanin inhibitor.
||Protein kinase inhibitors 1
||Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
||TDCPP is a chlorinated analog of tris(2,3-dibromopropyl)phosphate (Tris) which is one of the most detected organophosphorus flame retardants (OPFRs) in the environment.
||N3PT(N3-pyridyl thiamine) is a potent and selective transketolase(TK) inhibitor (IC50= 22 nM for Apo-TK) both in vitro and in vivo.
||HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).
||(2S)-Octyl-α-hydroxyglutarate ((2S)-Octyl-2-HG) is a modified form of S-isomer 2-Hydroxyglutarate.
||(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a modified form of D-isomer 2-Hydroxyglutarate.
||ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects .
||ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM.
||GSK2795039 is a novel small molecule NADPH Oxidase 2 Inhibitor.
||UNC1079 is the piperidine analog of UNC1021, as a structurally similar but significantly less potent inhibitor for use as a negative control in cellular studies.
||9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations.
||VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
||FAP-IN-1 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 3.2 nM; also inhibits prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM.
||HUHS015 is a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo.
||PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.
||Calcein-AM is cell-permeable fluorescent dye used to determine the cell viability.
||GNE-3511 is a potent and selective zipper kinase (DLK, MAP3K12) inhibitors.
||SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.
||EF-5 (EF5; 2-Nitroimidazole) is a hypoxia labeling agent used to identify hypoxia in cells.
||Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.
||HA15 is a molecule that targets specifically BiP/GRP78/HSPA5.
||Ro 48-8071 is an inhibitor of OSC (Oxidosqualene cyclase) with IC50 of appr 6.5 nM.
||RET Kinase inhibitor 1
||RET Kinase inhibitor 1 is a RET kinase inhibitor extracted from patent WO2014141187A1, compound example 27, has an IC50 of < 100 nM.
||tBID is a selective inhibitor of homeodomain–interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 µM.
||Fumarate hydratase-IN-1, an enzyme of the TCA cycle.
||Fmoc-1,6-diaminohexane is an analog of Osw-1 which can be used to treat Alzheimer's disease and cancer, extracted from patent US 20140135279 A1.
||Tetracosactide (INN) is a synthetic peptide and analogue of adrenocorticotrophic hormone (ACTH) .
||Efaproxiral sodium is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.
||Estradiol 3-sulfamate (BLE 00084; E2MATE; ES-J 995) is a potent, long-acting, and orally active steroid sulfatase inhibitor; inhibits estrone sulfatase with an IC50 of 251 nM and a Ki of 133 nM.
||HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
||HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.
||Glyoxalase I inhibitor free base
||Glyoxalase I inhibitor (free base) is a potent Glyoxalase I inhibitor, candidate for anticancer agents.
||Phorbol is a highly toxic diterpene, whose esters have important biological properties.
||CCT 007093 is an effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines.
||NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
||BAY-876 is the first highly selective GLUT1 inhibitor with IC50 of 0.002 uM.
||OICR-0547 is a closely related derivative of OICR-9429. OICR-942 is a novel small-molecule antagonist of the Wdr5-MLL interaction, while OICR-0547 cannot bind to WDR5.
||Fulvestrant (ICI 182780) R enantiomer
||Fulvestrant R enantiomer is the R enantiomer of Fulvestrant. Fulvestrant is a selective estrogen receptor (ER) antagonist which can be used to treat breast cancer.
||GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 20 μM in vivo, respectively.
||Tetrahydrouridine is potent inhibitor of cytidine deaminase (CDA), which competitively blocks the enzyme's active site more effectively than intrinsic cytidine.
||DMA is a fluorescent compound (λex=340 nm, λem=478 nm).
||Ro 48-8071 fumarate
||Ro 48-8071 fumarate is an inhibitor of OSC (Oxidosqualene cyclase) with IC50 of appr 6.5 nM.
||Gracillin is a kind of steroidal saponin isolated from the root bark of wild yam Dioscorea nipponica with antitumor agent.
||Tenacissoside H is a Chinese medicine monomer extracted, isolated from Caulis Marsdeniae Tenacissimae.
||Abiraterone metabolite 1
||Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal drug, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
||PDD 00017273 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), with an IC50 of 26 nM, and a KD of 1.45 nM.
||SAR405 R enantiomer
||SAR405 R enantiomer is an enantiomer of SAR405. SAR405 is a PIK3C3/Vps34 inhibitor.
||Panaxadiol is a novel antitumor agent extracted from the Chinese medical herb Panax ginseng.
||NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial.
||Ac-DEVD-AFC is a fluorogenic substrate (λex=400 nm, λem=530 nm).
||EC330 is a leukemia inhibitory factor (LIF) inhibitor.
||Solamargine is a major steroidal alkaloid glycoside extracted from a traditional Chinese medicinal herb, Solanum nigrum L. (SNL); has been shown to inhibit growth and induce apoptosis of various cancer cells.
||Arctiin(NSC 315527), a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.
||Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.
||Calycosin (Cyclosin) is a natural active compound with anti-oxidative and anti-inflammation activity.
||DMA trihydrochloride is a fluorescent compound (λex=340 nm, λem=478 nm).
||Cy5.5 is a near-infrared fluorescent dye used to label biological molecules, such as peptides, proteins, and oligonucleotides.
||Glucoraphanin, a natural glucosinolate found in cruciferous vegetable, is a stable precursor of the Nrf2 inducer sulforaphane, which possesses antioxidant, anti-inflammatory, and anti-carcinogenic effects.
||5α-Pregnane-3β,6α-diol-20-one is a mitogenic metabolite of progesterone, and it can be produced in starved androgen-responsive prostate cancer cells.
||Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.
||5,15-Diacetyl-3-benzoyllathyrol is one of the lathyrane diterpenoids, that has anti-cancer activity.
||3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
||Glyoxalase I inhibitor
||Glyoxalase I inhibitor is a potent Glyoxalase I inhibitor, candidate for anticancer agents.
||Zotarolimus is a tetrazole-containing Rapamycin analog which is used as animmunomodulator, and is useful in the treatment of restenosis, immune, and autoimmune diseases.
||42-(2-Tetrazolyl)rapamycin is a prodrug compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.
||Collagen proline hydroxylase inhibitor-1
||Collagen proline hydroxylase inhibitor-1 is an antifibroproliferative agents.
||Collagen proline hydroxylase inhibitor
||Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents.
||Miquelianin (Quercetin 3-O-glucuronide) is a metabolite of quercetin and a type of natural flavonoid.
||Hoechst 33258 is a fluorescent dyes, which can be used as a cell dye for DNA.
||Hoechst 33258 3HCl
||Hoechst 33258 trihydrochloride is a fluorescent dyes, which can be used as a cell dye for DNA.
||Cephalotaxine is an antiviral as well as antitumor agent.
||Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in researching disorders of the gallbladder and pancreas.
||Sotetsuflavone is a potent inhibitor of DENV-NS5 RdRp (Dengue virus NS5 RNA-dependent RNA polymerase) with an IC50 of 0.16 uM, is the most active compound of this series .
||Topilutamide is a topical nonsteroidal antiandrogen (NSAA).
||6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer.
||NADPH tetrasodium salt
||NADPH tetrasodium salt is a ubiquitous cofactor and biological reducing agent that acts as an electron donor in many biological reactions.
||Harringtonine, a natural Cephalotaxus alkaloid, is an inhibitor of protein synthesis.
||3β, 7β, 17β-Trihydroxyandrost-5-ene
||3b,7a,17a-Trihydroxyandrost-5-ene is a immune modulator extracted from patent US20030060425.
||Tirapazamine(SR259075; Win59075; SR4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen; a phenomenon known as tumor hypoxia.
||Geniposidic acid is an effective anticancer and radioprotection agent.
||Bavachalcone is a major bioactive compounds isolated from Psoralea corylifolia L.; has been widely used as traditional Chinese medicine; antibiotic or anticancer agent.
||Tetrahydroxyquinone is a molecule best known as a primitive anticataract drug, is also a highly redox active molecule that can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS).
||N-Acetylcadaverine is the acetylated form of the polyamine cadaverine.
||(E)-2-Decenoic acid is an interesting fatty acid isolated from royal jelly secretions of honey bees.
||Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
||Lathyrol is a natural product, and is used for cancer treatment.
||Emeramide is a novel lipid-soluble, thiol-redox antioxidant and heavy metal chelator.
||HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC50 of 29.8 µM in A375 cells.
||N-Desethyl Sunitinib is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively.
||F16 is a small molecule that selectively inhibits proliferation of mammary epithelial, neu-overexpressing cells, as well as a variety of mouse mammary tumor and human breast cancer cell lines.
||NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.
||YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.
||Cyclic somatostatin is a growth hormone-release inhibiting factor used in the treatment of severe, acute hemorrhages of gastroduodenal ulcers.
||Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.
||Bruceantin(NSC165563) is first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice.
||(-)-Gallocatechin gallate is the polyphenol isolated from tea, with cancer-preventive activities.
||Timonacic is used as an adjuvant in the treatment of acute and hepatic disorders. It has also been used for the treatment of some cases of cancer, through the induction of the reverse transformation.
||ITE is a aryl hydrocarbon receptor (AhR) agonist with Ki of 3 nM, and the estimated IC50 of ITE for OVCAR-3 cell proliferation was 0.2 nM.
||Nitracrine is an antitumor drug that has been used clinically for several years.
||Arenobufagin is a natural bufadienolide from toad venom; has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells.
||Bufalin a major digoxin-like immunoreactive component of the Chinese medicine Chan Su; has been shown to exert a potential for anticancer activity against various human cancer cell lines in vitro.
||Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.
||Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB.
||Bufotalin is a cardiotoxic bufanolide steroid, cardiac glycoside analogue, secreted by a number of toad species; a novel anti-osteoblastoma agent.
||ADDA 5 HCl
||ADDA 5 hydrochloride is a partial non-competitive inhibitor of cytochrome c oxidase (CcO), with IC50s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively.
||Daucosterol is a natural sterolin.
||Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells.
||Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.
||HI-TOPK-032 is a potent and specific TOPK inhibitor.
||Lurbinectedin (PM01183) is a new DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively.
||Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy.
||Canthaxanthin is a red-orange carotenoid with various biological activities, such as antioxidant, antitumor properties.
||Urethane has been used as an antineoplastic agent and for other medicinal purposes.
||Teriparatide (PTH 1-34)
||Teriparatide is a PHT agonist, binds to the receptor for PHT present in bone and stimulates the G-protein-related production of cyclic monophosphate.
||Troloxa is a cell-permeable and water-soluble vitamin E analogue and is a powerful antioxidant.
||Anethole trithione is a drug used in the treatment of dry mouth， being studied in the treatment of cancer.
||Corylin is a major bioactive compound isolated from Psoralea corylifolia L; antibiotic or anticancer compound.
||Pipobroman is an anti-cancer drug that probably acts as an alkylating agent.
||Protodioscin, a major steroidal saponin in dioscoreae rhizome, has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.
||pentagastrin is a synthetic polypeptide that has effects like gastrin when given parenterally，which can cause the secretion and synthesis of salivary proteins.
||Coelenterazine is widely distributed among marine organisms which can produce bioluminescence by calcium-dependent oxidation mediated by the photoprotein aequorin.
||Sucralose is an intense organochlorine artificial sweetener.
||URB602 is a selective monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL with IC50 of 28±4 μM through a noncompetitive mechanism.
||Glycerol is a clear, colourless, viscous, sweet-tasting liquid. Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.
||Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system.
||(+)-α-Tocopherol is a vitamin E derivative. vitamin E is a fat-soluble antioxidant.
||Imexon is an iminopyrrolidone aziridine with anti-cancer activity.
||Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.
||Schisandrin C is a phytochemical lignan isolated from Schizandra chinensis Baill; shows anticancer-effects in human leukemia U937 cells.
||Alpha-mangostin is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a Ki of 2.85 μM.
||5-IAF is an idoacetamide derivate of fluoresceine.
||Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that participates in glycogen metabolism and synthesis of RNA during transcription.
||R162 is a potent inhibitor of glutamate dehydrogenase 1 (GDH1), with anti-cancer properties.
||ATN-224 is an oral Cu2+/Zn2+-superoxide dismutase 1 (SOD1) inhibitor. ATN-224 inhibits SOD1 activity in endothelial cells, an effect that is dose dependent with an IC50 of 17.5±3.7 nM.
||MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.
||Importazole is a small molecule inhibitor of the nuclear transport receptor importin-β.
||Psoralen(Furocoumarin) is an active ingredient from Fructus Psoraleae; has anticancer activity.
||Perhexiline maleate is a potent carnitine palmitoyltransferase 1 (CPT 1) inhibitor with IC50s of 77 and 148 μM for rat heart and liver CPT 1, respectively.
||Pulsatilla saponin D (SB365)
||Pulsatilla saponin D(SB365) isolated from the root of Pulsatilla koreana, has exhibited potential beneficial effects as a chemopreventive agent for critical health conditions including cancer.
||CBR-5884 is a novel and noncompetitive 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor with IC50=33 μM).
||L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.
||1-Acetyl-3-o-toluyl-5-fluorouracil is a potent an antineoplastic agent.
||TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively.
||Brassinolide is a predominant plant growth modulator that regulate plant cell elongation.
||Atractylenolide III is a major component of Atractylodes rhizome can induce apoptosis of the lung carcinoma cells.
||Atractylenolide II is a sesquiterpene compound isolated from the dried rhizome of Atractylodes macrocephala (Baizhu in Chinese); anti-proliferative activity.
||NVX-207 is a derivative of betulinic acid with anti-cancer activity.
||Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate with the antitumor activity.
||Hydroxysafflor yellow A
||Hydroxysafflor yellow A is a flavonoid derived and isolated from traditional Chinese medicine Carthamus tinctorius L., possesses anti-tumor activity.
||Castanospermine inhibits all forms of α- and β-glucosidases, especially glucosidase l (required for glucoprotein processing by transfer of mannose and glucose from asparagine-linked lipids).
||Trichlormethine hydrochloride is a cytostatic agent in the treatment of cancer and arthritis; shows carcinogenic effects to humans.
||2OH-BNPP1 is an inhibitor of BUB1 kinase, a Ser/Thr kinase, used for the treatment of cancer.
||PSI-697is a P-selectin inhibitor.
||Rabacfosadine (GS-9219), a novel prodrug of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
||23-hydroxybetulinic acid is one of the bioactive components responsible for its anticancer activity.
||Ecteinascidin-Analog-1 is a useful intermediate for chemical sythesis of Ecteinascidin analogues; Ecteinascidins is a family of tetrahydroisoquinoline alkaloids with wide range of antitumor and antimicrobial activities.
||LM985 is one of a series of compounds based on the flavone ring structure, with anti-tumor activities.
||BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
||HJC0350 is a potent and specific EPAC2 antagonist with an IC50 of 0.3 µM.
||BAMB-4(ITPKA-IN-C14) is a new membrane-permeable inhibitor against inositol-1,4,5-trisphosphate-3-kinase A((ITPKA) with IC50 of 37 uM in ADP-Glo Assay.
||Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications.
||Luciferase is a class of enzyme which could oxidize D-luciferin to chemically generate visible light, and is widely used for biological assays and imaging.
||Hyaluronic acid sodium salt
||Hyaluronic acid sodium salt is a biopolymer composed of repeating units of disaccharides with various applications.
||Gastrin-Releasing Peptide, human
||Gastrin-Releasing Peptide, human (GRP) belongs to the bombesin-like peptide family, and is not a classical hypothalamic-hypophyseal regulatory hormone since it plays only a perfunctory role in the mediation of pituitary hormone release.
||QS11 is a GTPase activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor.
||FPH2 induces of functional proliferation of primary human hepatocytes and may lead to the development of new therapeutics for liver diseases.
||Brequinar is a potent inhibitor of dihydroorotate dehydrogenase, with potent activities against a broad spectrum of viruses.
||Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors.
||Kallikrein Inhibitor is a synthetic peptide. The synthetic kallikrein inhibitor can attenuate breast cancer cell invasion.
||Esonarimod is an antirheumatic drug.
||DL 071-IT HCl
||DL 071-IT is a potent non-selective beta-adrenoceptor antagonist.
||QCC-374 is prostanoid agonist potentially for the treatment of pulmonary arterial hypertension.
||SPI-112Me is a prodrug for SPI-112, which preferentially inhibits the PTPase activity of Shp2 over Shp1 and PTP1B by a factor of 20 in cell-free assays.
||Pyronaridine, also known as Malaridine, is an antimalarial drug.
||A novel Ehp inhibitor
||A novel Ehp inhibitor
||LGD-3303 is a drug which acts as a selective androgen receptor modulator (SARM), with good oral bioavailability.
||CycLuc1 is a luciferase substrate which offers brighter bioluminescence and improved imaging in mouse models at lower doses than the standard D-luciferin.
||MDK-1088, also known as T.cruzi Inhibitor, is a Trypanosoma cruzi inhibitor. MDK-1088 has CAS#1350920-22-7 . The last 4 digit f CAS# was used in its name.
||MDK74978, also known as Multi-kinase inhibitor I, is a Multi-kinase inhibitor. MDK74978 has CAS#778274-97-8. The last 5 digit was used in its name.
||MDK-8582, also known as Hnps-PLA Inhibitor, is an nhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
||Methyl 13-cis-4-Oxoretinoate is a bioactive chemical.
||Cyantraniliprole(HGW-86) is an insecticide of the ryanoid class; has activity against pests such as Diaphorina citri that have developed resistance to other classes insecticides.
||ADT-OH is a derivative of anethole dithiolethione (ADT) and synthetic hydrogen sulfide (H2S) donor.
||Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.
||ALKS-8700 also known as diroximel fumarate, is a prodrug of monomethyl fumarate in a controlled-release formulation that rapidly and efficiently converts to MMF in the body.
||SPI 112 is novel Shp2 PTP inhibitor.
||AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 .
||Gemcitabine monophosphate disodium salt, also called GemMP, is a monophosphate derivative of Gemcitabine.
||Acecainide, also known as N-acetylprocainamide and ASL 601, is the N-acetylated metabolite of procainamide.
||An antimicrobial agent used as a substitute for chlorophenols
||SU 5205 is a VEGFR2 inhibitor.
||SU 4942 is a bioactive chemical.
||SU 4313 is a bioactive chemical.
||NSC 247030 is a bioactive chemical.
||Brevianamide F , also known as cyclo-(L-Trp-L-Pro), belongs to a class of naturally occurring 2,5-diketopiperazines.
||Cyclo (RGDfC), avb3 Integrin Binding Cyclic RGD Peptide,This is a cyclic RGDfC sequence, an integrin avb3-affine peptide.
||S-2765 is specific to activated factor X (FXa),short peptide covalently bound to pNA (4-nitroaniline).
||CP 376395 is a potent and selective Corticotropin releasing factor 1 (CRF1) receptor antagonist.
||Cyazofamid is a foliar fungicide approved for use in the EU.
||BT-11 is an orally available LANCL2 binding compound for treating inflammatory bowel disease.
||ST271 is a potent inhibitor of protein tyrosine kinase (PTK).
||Toxoflavin is an inhibitor of survivin expression and antagonist of Tcf4/b-catenin signaling
||LH 21 is a 1,2,4-triazole that acts as a cannabimimetic.
||ARM390 is a non-peptidic, low-internalizing δ-selective opioid receptor agonist.
||Torsemide is a pyridine-sulfonyl urea type loop diuretic.
||Selamectin is an anthelminthic which can be used on dogs and cats.
||4P-PDOT, also known as 4-phenyl-2- propionamidotetralin, is a MT2-receptor-specific antagonist. MT2 melatonin receptor may be a novel target for analgesic drug development.
||Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes.
||Etizolam(AHR3219; Y7131) is a benzodiazepine analog.
||EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
||TTPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.
||MELK-8a is a novel MELK inhibitor.
||DprE1-IN-1 is a potent DprE1 inhibitor, with ic50 of 10 nM, also inhibits PDE6, with IC50 of 6 uM.
||(+)-Narwedine. Galantamine(Narwedin) is a competitive and reversible cholinesterase(AChE) inhibitor.
||(+)-Etomoxir (sodium salt)
||A PPARα agonist and an irreversible CPT-1 inhibitor.
||PP2 analog is the analog of PP2,a Src family kinase inhibitor.
||Naloxegol is the first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
||Dihydroethidium(Hydroethidine; PD-MY 003) is a superoxide indicator; exhibits blue-fluorescence in the cytosol until oxidized, where it intercalates within the cell's DNA, staining its nucleus a bright fluorescent red.
||LSN2814617 is a neurotoxic positive allosteric modulator.
||The N-dealkylated metabolite (M1) of Atazanavir (A790051), a HIV protease inhibitor.
||Fabomotizole is an anxiolytic drug; produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.
||Etofenamate is a non-steroidal anti-inflammatory drug used for the treatment joint and muscular pain.
||Statil is shown to be a potent aldose reductase inhibitor.
||Ametantrone is a new anthracenedione antineoplastic agents, produced a concentration-dependent inhibition of hepatic microsomal lipid peroxidation.
||Ro 61-8048 is a potent and selective inhibitors of kynurenine hydroxylase with IC50 of 37 nM.
||RGW 611 is a morpholine derivative.
||PTZ-343 is a phenothiazine derivative with chemical name: sodium 3-(10H-phenothiazin-10-yl)propane-1-sulfonate.
||TPT-260 2Hcl (TPU260 2Hcl) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this molecule as TPT-260.
||S-2238 is specific to thrombin, is a short peptide covalently bound to pNA (4-nitroaniline).
||GSK3008348 is a potent and selective inhibitor being developed as the first inhaled inhibitor of the αvβ6 integrin for the treatment of IPF.
||A selective Δ6 desaturase inhibitor that displays selectivity over Δ5 and Δ9 desaturases
||4-Chloro-α-cyanocinnamic acid (α-CHCA) is a classic monocarboxylate transporters (MCT) inhibitor. α-cyano-4-hydroxycinnamate (CHC) has a 10-fold selectivity for MCT1 compared to other MCTs.
||GC376 is a 3CLpro inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM.
||ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
||Tafamidis(Fx1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
||Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.
||Leonurine, a natural alkaloid extracted from Herba leonuri, has been proved to have anti-inflammatory effect.
||PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.
||PCO371 is a novel, orally active small molecule that acts as a full agonist of PTHR1.
||A compound potently inhibits RNA polymerase I transcription in A375 Malignant Melanoma cell line, while has no effects on polymerase II.
||GSK-2018682 is a sphingosine 1 phosphate receptor (S1PR)-1 agonist potentially for the treatment of multiple sclerosis.
||VPS34 inhibitor (Compound80)
||A-196 is a potent and selective chemical inhibitor of SUV420H1 and SUV420H2 that inhibits the di- and trimethylation of H4K20me in multiple cell lines.
||KG-501 is a small molecule inhibitor of Aldolase, Histochemical substrate for alkaline phosphatases.
||Gea 3162 is a potent inhibitor of ADP-induced platelet aggregation in platelet rich plasma (PRP). GEA 3162 stimulates cGMP production in platelets, granulocytes, and polymorphonuclear leukocytes.
||GYY4137 morpholine salt
||GYY4137 is a slow-releasing H2S compound with vasodilator and antihypertensive activity.
||KYP-2047 is a very potent, selective inhibitor of Prolyl oligopeptidase (POP), also known as prolyl endopeptidase (PEP or PE). Ki = .023nM (porcine).
||Z-IETD-pNA is a colorimetric caspase-8/granzyme B substrate containing the benzyloxycarbonyl (Z) moiety.
||Velaresol, also known as BW12C or BW12C79, is a oxyhaemoglobin stabilizer.
||Adipamidoxime(NSC 70868) is a new bioactive compoud.
||Cosan-528 is a bioactive chemical.
||Sematilide, also known as CK-1752, is a class III antiarrhythmic.
||Butyryltimolol is a lipophilic ester prodrug of timolol, a beta adrenergic blocer with antihypertensive and hemodynamic properties.
||NSC 191412 is a bioactive compound.
||U 19963 is a bioactive compound.
||Probucol is an effective inhibitor of ABCA1-mediated cholesterol efflux without influencing scavenger receptor class B type I–mediated efflux.
||NSC 6038 is a bioactive compound.
||Tomatidine hydrochloride is a steriodal alkaloid structurally sumilar to cyclopamine (sc-200929) but does not inhibit hedgehog pathway. It can be employed as a negative control for cyclopamine (sc-200929) and KAAD-cyclopamine.
||Arecaidine but-2-ynyl ester tosylate is a potent muscarinic agonist that shows 4.6-fold that is selectivity for mAChR M2 in the atrium versus those in the ileum.
||AVex-73 is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease
||Alovudine is a DNA polymerase subunit gamma-1 (POLG) inhibitor, shows promise for treating AML.
||NSC 31205 is a PIM2/1 inhibitor.
||Thiambutosine was a candidate for treatment of lepromatous leprosy.
||LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.
||IT 901 is a c-Rel inhibitor (IC50 = 3 μM). Inhibits IL-2 expression in activated T-cells in vitro.
||Methyl cellulose (or methylcellulose) is a chemical compound derived from cellulose. It is not digestible, not toxic, and not an allergen. Methyl cellulose is widely used in drug formuation for oral adminstration.
||DSP-2230 is a selective Nav1.7/Nav1.8 blocker.
||MC180295 (MC-180295, MC 180295) is a novel potent, highly selective CDK9 inhibitor with IC50 of 5 nM, displays >22-fold selectivity over other CDKs.
||Deoxynyboquinone (NSC 165572）.
||BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2.
||TDI-2760 si a small molecule Aβ-aggregation inhibitor that not only shows a strong inhibitory efficacy toward the Aβ-fibrinogen interaction (IC50=1.67 uM) but also retains potency toward the Aβ42 aggregation inhibition process.
||SEN1269 is a novel potent Aβ aggregation inhibitor that binds to monomeric Aβ1-42 with Kd of 4.4 uM, protects neuronal cell lines against an Aβ1-42 insult with IC50 of 15 uM.
||A potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 0.13 uM, >385-fold selectivity over ChoKβ.
||TRO 40303 is a novel cardioprotective compound that delays mitochondrial permeability transition pore (mPTP) opening, binds specifically to TSPO at the cholesterol site (Ki=150 nM).
||PAFAH inhibitor P11 (P11) is a potent, selective platelet-activating factor acetylhydrolases PAFAH1b2 and PAFAH1b3 inhibitor with IC50 of 40 nM and 900 nM respectively.
||A polyamine oxidase (PAO) inhibitor that inhibits spermine oxidase and N1-acetylpolyamine oxidase with IC50 of 6.1 and 0.02 uM, respectively.
||Visomitin (SKQ1 bromide.
||Meayamycin is an analogue of FR901464 that binds to the splicing factor 3b (SF3b) complex and inhibits pre-mRNA splicing, shows picomolar antiproliferative activity against various cancer cell lines and multidrug-resistant cells.
||A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 2.8 uM, inhibits the phosphorylation of OAG to OAPA with IC50 of 3.8 uM in intact platelets.
||A small molecule NADH oxidase ENOX1 inhibitor with IC50 of 10 uM.
||ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain.
||iMDK is a small molecule inhibitor of the growth factor Midkine (MDK) that suppresses the endogenous expression of MDK but not other growth factors such as PTN or VEGF.
||JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures.
||A potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.0 uM, 33-fold selectivity over ChoKβ.
||GRF (1-44), human
||The parent molecule of several peptides recently extracted from pancreatic tumours associated with acromegaly.
||p32 inhibitor M36
||p32 inhibitor M36 is a novel small molecule inhibitor of p32 mitochondrial protein, binds directly to p32 and inhibits p32 association with LyP-1.
||The single isomer, 5-FAM, contains a carboxylic acid that can be used to react with primary amines via carbodiimide activation of the carboxylic acid. Fluorescein is the most common fluorescent derivatization reagent for labeling biomolecules. In addition to its relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility, fluorescein has an excitation maximum that closely matches the 488 nm spectral line of the argon-ion laser.
||Juniferdin is a small molecule, potent Protein disulfide isomerase (PDI) inhibitor with IC50 of 156 nM, inhibits PDI-mediated reduction of HIV-1 envelope glycoprotein gp120.
||A ceramide analog that inhibits glucosylceramide synthase (GCS), reduces the synthesis of sphingosine and its derivatives, increases cellular ceramide, and induces cell cycle arrest. .
||Aβ polymerization stimulator O4
||Aβ polymerization stimulator O4 is an orcein-related small molecule can drive polymerization of amyloid-β (Aβ).
||The one form of glutamic acid found in nature, is the most potent natural inhibitor of glutathione synthesis.
||GW-4869 (GW4869, GW 4869) is a cell-permeable, potent, specific, non-competitive inhibitor of neutral sphingomyelinase (nSMase) with IC50 of 1 uM.
||Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).
||Pyrimidinone 8 is a novel allosteric, non-competitive divalent metal transporter-1 (SLC11A2/DMT1) inhibitor with Ki of 20 uM.
||The prodrug of modafinil that is a mild central nervous system stimulant drug used to relieve excessive sleepiness and inattention.
||E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo.
||AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat.
||TRX-0237 Methylate (Hydromethylthionine, Methylene blue) is a Tau aggregation inhibitor (TAI) with Ki of 0.12 uM for intracellular TAI activity.
||L-Thyroxine sodium salt pentahydrate
||A manufactured form of the thyroid hormone thyroxine (T4) that typically used to treat hypothyroidism.
||A compound that exhibits anti-inflammatory and immunomodulatory effects by inhibiting lipid mediator and cytokine release from inflammatory cells and interfering with PDGF- and TGF-β1-induced proliferation and migration of vascular medial smooth muscle cells.
||A manufactured form of the thyroid hormone thyroxine (T4) that typically used to treat hypothyroidism.
||A toxic byproduct, iminoquinone metabolite of acetaminophen that covalently binds to the active site of MIF.
||GGTI 2417 is the methyl ester prodrug of GGTI-2418, a highly potent, competitive, and selective inhibitor of GGTase I.
||A novel MPT (mitochondrial permeability transition) inhibitor of that inhibits Ca2+-induced MPT in rat liver isolated mitochondria.
||5MPN is a first-in-class, selective, competitive, orally available inhibitor of PFKFB4 with Ki of 8.6 uM, does not inhibit PFK-1 or PFKFB3.
||T-025 is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
||SAN9812 (Carnostatine) is a potent, highly selective, competitive inhibitor of Carnosinase 1 (CN1) activity with Ki of 11 nM.
||RU-521 (RU.521, RU-320521) is a potent, selective cyclic GMP-AMP synthase (cGAS) inhibitor with Kd of 36.2 nM.
||PF-794 (PF794) is a potent, specific and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with IC50 of 39 nM in cell-free assays.
||PF-06928215 (PF06928215) is a high affinity Cyclic GMP-AMP synthase (cGAS) inhibitor with Kd of 200 nM, IC50 of 4.9 uM.
||P053 (P-053, CerS1 inhibitor P053) is a potent, selective, orally active inhibitor of ceramide synthase 1 (CerS1) with IC50 of 0.5 uM, displays >10-fold selectivity for inhibition of CerS2, CerS4, CerS5, and CerS6.
||LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays.
||KuWal151 is a potent, selective cdc2-like kinase (CLK) inhibitor with IC50 of 88/510/28 nM for CLK1/2/4, respectively.
||Karonudib (TH1579) is an analogue of TH588, a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo..
||JTT-551 sodium (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR.
||CWP-232228 is a highly potent small-molecule Wnt/β-catenin signaling inhibitor that targets the β-catenin/Tcf4 interaction in the nucleus.
||CLK2 inhibitor Indazole1
||CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases.
||ARN-3261 is a potent, selective, orally available salt inducible kinase SIK2 and SIK3 inhibitor with IC50 of 11 nM and 19 nM, respectively.
||A potent, specific, irreversible NIMA-related Kinase 2 (NEK2) inhibitor with IC50 of 16.65 nM.
||A potent, specific divalent metal transporter 1 (DMT1) inhibitor that inhibits Mn incorporation in HEK293 cells with IC50 of 0.3 nM.
||A potent, selective, orally available RET kinase inhibitor with potential antineoplastic activity.
||A potent, selective G protein-coupled receptor kinase GRK2 inhibitor with IC50 of 8 nM.
||Nek2 inhibitor 72
||A potent, ATP-competitive and relative selective Nek2 inhibitor with IC50 of 0.27 uM.
||A novel small molecule inhibitor that inhibits PP2A and β-catenin interaction by selectively engaging PR55α binding site (Kd=45 pM).
||A cell-permeable small molecule inhibitor of Fumarase (fumarate hydratase), an enzyme of the tricarboxylic acid cycle (TCA cycle).
||CAT639 is an improved analog of ATV399 that exhibits improved β-cell viability and insulin secretion in the rat insulin-producing INS1E cells and primary rat dispersed islet cells, inhibits dimerization of iNOS.
||TiY (TIC Fluorescent Probe TiY) is the first TIC (tumor initiating cell)-specific fluorescent chemical probe, target vimentin, a marker for epithelial-to-mesenchymal transition (EMT).
||ERD03 (EXOSC3-RNA disrupting compound 3) is a small molecule EXOSC3-RNA disrupting (ERD) compound that binds specifically to EXOSC3 (Kd=17 uM), induces a PCH1B-like phenotype in zebrafish.
||DNS-pE2 is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells.
||DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells.
||A potent, selective S1P3 antagonist with Ki of 0.25 nM.
||A potent, pure aryl hydrocarbon receptor (AHR) antagonist (IC50=62 nM) devoid of partial agonist potential.
||An allosteric, sepecific inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase with IC50 of 6.2 uM in FP assyas.
||Pexmetinib (ARRY-614) is a potent, orally active, dual Tie-2/p38 MAPK inhibitor with IC50 of 1, 26 and 35 nM for Tie-2, p38α and p38β, respectively.
||A potent, orally active gap-junction modifier.
||A potent, orally active gap-junction modifier.
||A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.
||A potent and selective (up to 263-fold) inhibitor of breast cancer cells with GI50 of 0.5 uM (MCF-7), via activation the aryl hydrocarbon receptor (AhR) pathway.
||SPA70 is a potent and selective hPXR antagonist (IC50=0.51 uM) that interacts with the ligand-binding domain (LBD) of hPXR, inhibits hPXR in human hepatocytes and mouse models and enhances the chemosensitivity of cancer cells.
||GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.
||A novel potent, selective, competitive and orally active DPP4 inhibitor with potential for the treatment of type 2 diabetes.
||TAK-100 is a potent, selective and orally active inhibitor of DPP-4 with IC50 of 5.3 nM, shows no inhibition on DPP2/8/9.
||A small molecule inhibitor of HECT-type ubiquitin ligase with IC50 of 6.8/6.3/6.9 uM for Smurf2/Nedd4/WWP1, respectively.
||Mapracorat (ZK 245186) is a potent, selective and non-steroid glucocorticoid receptor (GR) agonist with binding Ki of 1.9 nM.
||TG693 is an orally available, selective, ATP-competitive CLK1 inhibitor with IC50 of 112.6 nM.
||GATA4 activator 7
||A novel small molecule that activates GATA4/NKX2-5 transcriptional synergy with EC50 of 7 uM in cell reporter assay. .
||A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
||A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
||A potent, selective and GABA transporter 1 (GAT1) inhibitor with IC50 of 0.13 uM for hGAT1.
||MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.
||A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.
||Loteprednol etabonate is an anti-inflammatory corticosteroid used in optometry and ophthalmology.
||AA-861 (Docebenone) is a potent, selective 5-Lipoxygenase (5-LO) inhibitor with IC50 of 0.8 uM.
||A potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 0.77 nM.
||A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.
||A potent calcium sensing receptor (CaSR) negative allosteric modulator with IC50 of 146 nM for hCaSR.
||3-Bromo-7-Nitroindazole is a more potent inhibitor of nNOS than 7-nitroindazole in vitro, is also potent against iNOS, inhibits rat nNOS, bovine eNOS, and rat iNOS with IC50 of 0.17, 0.86, and 0.29 uM.
||A small molecule inhibitor of PP2C that activates extensive 3' cleavage at a concentration 50-fold below that required by fluoride or CP.
||CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively.
||A potent and selective inhibitor of breast cancer cells via activation the aryl hydrocarbon receptor (AhR) pathway.
||A potent calcium sensing receptor (CaSR) negative allosteric modulator with IC50 of 146 nM for hCaSR.
||BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM.
||A potent, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 0.053 and 5.0 nM, respectively.
||A 1,2,5-thiadiazolidin-3-one-1,1-dioxide scaffold for design of protein tyrosine phosphatase-1B (PTP1B) inhibitor.
||Tasisulam (LY 573636) is a small molecule antitumor agent that induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death.
||SP 4206 is a high-affinity (Kd=70 nM) small molecule that blocks blocks the binding of the IL-2α receptor (IL-2Rα) to IL-2.
||A synthetic immunosuppressant that functions as a S1P1 receptor agonist.
||Guanabenz (WY 8678) is an α2 adrenergic receptor agonist that is used as an antihypertensive agent.
||Prednisolone is a glucocorticoid with the general properties of the corticosteroids. .
||A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.
||A potent, allosteric inhibitor of CBFβ-RUNX1 interaction with IC50 of 3.2 uM in FRET assays.
||A potent, selective and orally active CRF1 receptor antagonist with IC50 of 6.1 nM, >1,000-fold selectivity over CRF-binding protein and biogenic amine receptors.
||NDT 9513727 is a potent, selective and orally bioavailable C5a receptor inverse agonist with IC50 of 11.6 nM in radioligand binding assay.
||An orally available, potent and selective ileal bile acid transporter (IBAT) inhibitor for the treatment of constipation.
||A novel SCFSkp2 inhibitor that reduces Skp2 binding to Cullin-1 and Commd1, synergistically enhances BTZ-induced apoptosis.
||A potent, selective, non-competitve inhibitor of 15-lipoxygenase (15-LOX) with Ki of 197 nM.
||A potent and orally active non-peptide C5a receptor (CD88.
||A potent Cdc25 dual specificity phosphatase inhibitor with IC50 of 2-6 uM for Cdc25A/B/C.
||ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS.
||A key bioactive small molecule identified in Tripterygium wilfordii Hook F., has a broad spectrum of biological functions.
||Carnosic acid (Carnosate) is a naturally occurring phenolic compound with antioxidant, anti-inflammatory and antimicrobial properties, inhibits the BCL9/β-catenin interaction with Ki of 3.3 uM.
||Leukadherin 1 (LA1) is a small molecule allosteric agonist of integrin CD11b/CD18 (CR3), increases CD11b/CD18-dependent cell adhesion to fibrinogen (EC50=4 uM).
||The L-lysylamide prodrug of 5F-203 (NSC703786), a potent, selective antitumour agent through activation the aryl hydrocarbon receptor (AhR) pathway.
||A highly potent and orally bioavailable non-peptide antagonist of luteinizing hormone-releasing hormone (LHRH) receptor with binding and functional IC50 of 0.1 and 0.06 nM for human LHRH, respectively.
||A potent, selective galanin-3 receptor (Gal3) antagonist with Ki of 17.44 nM, displays highly selective for Gal3 over the Gal1 and Gal2 subtypes (both Ki >10 uM).
||A benzodiazepine inhibitor that directly interacts with RUNX1 and CBFβ, represses RUNX1/CBFβ-dependent transactivation in reporter assays.
||VX-148 is a potent, uncompetitive, orally bioavailable IMPDH inhibitor with Ki of 6 nM against IMPDH type II enzyme.
||OTX008 (Calixarene 0118, PTX-008) is a is a calixarene derivative designed to bind the Galectin-1 (Gal1) amphipathic β-sheet conformation.
||A potent, selective antitumour agent through activation the aryl hydrocarbon receptor (AhR) pathway.
||A potent, selective nonpeptide antagonist of anaphylatoxin C3a receptor (C3aR) with IC50 of 200 nM.
||A potent, selective TAK1 inhibitor with IC50 of 8 nM, displays >33-fold and >62-fold selectivity over MEKK1 and MEKK4 respectively.
||Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).
||Rupintrivir (AG-7088, AG7088) is a potent, irreversible inhibitor of human rhinovirus 3C protease, inhibits the replication of all HRV serotypes with EC50 of 23 nM and EC90 of 82 nM.
||ZL0454 is a potent, highly selective small-molecule BRD4 inhibitor with IC50 of 49 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively.
||ZL0420 is a potent, highly selective BRD4 inhibitor with IC50 of 27 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively.
||Dynarrestin is a novel inhibitor of cytoplasmic Dyneins 1 and 2, acts reversibly to inhibit cytoplasmic dynein 1-dependent microtubule binding and motility in vitro without affecting ATP hydrolysis.
||Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300.
||SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1.
||PMX53 (Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)) is a potent C5a receptor (CD88) antagonist with IC50 of 20 nM, also is an agonist for Mas-related gene 2 (MrgX2) in human mast cells.
||RMC-4550 (RMC4550) is a potent, selective, allosteric inhibitor of SHP2 with IC50 of 0.58 nM (full-length SHP2 enzyme), suppresses pERK signaling in Calu-1 cells with IC50 of 7 nM.
||A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).
||SHP2-IN-2 is a selective, allosteric inhibitor of protein tyrosine phosphatase SHP2, preferentially inhibits SHP2 F285S over the PTP domain and allosteric site mutant.
||ABBV-744 (ABBV744) is a potent, BDII-selective BET bromodomain inhibitor, ABBV-744 is a potent, selective inhibitor of the AR transcription activity.
||A highly potent and selective inhibitor of CBP/p300 bromodomain with Kd of 0.23/0.47 uM respectively, with high selectivity over all other BD families, including the BET family.
||LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively.
||LLS2 is a novel potent Galectin-1 (Gal1) inhibitor that decreases membrane-associated H-Ras and K-Ras and contributed to the suppression of pErk pathway.
||Mtphagy Dye is a small-molecule fluorescent probe for visualizing mitophagy.
||SJB7 is a close analog of SPA70 and hPXR agonist, interacts with the ligand-binding domain (LBD) of hPXR.
||WNK inhibitor 7
||A potent, selectiive inhibitor of WNK1 kinase with IC50 of 95 nM, shows IC50 of 1.39 uM in the cellular OSR1 phosphorylation assay with reasonable aqueous solubility.
||WNK inhibitor 11
||WNK inhibitor 11 is a potent, selectiive and orally active inhibitor of WNK1 kinase with IC50 of 6 nM, 1,000-fold selectivity over WNK4 and 57-fold selectivity over WNK2.
||WNK inhibitor 12
||A potent, selectiive and orally active inhibitor of WNK1 kinase with IC50 of 6 nM, 1,000-fold selectivity over WNK4 and 57-fold selectivity over WNK2.
||A potent, selective IMPDH2 inhibitor that covalently binds to Cys140 with IC50 of 620 nM (inhibition of NO production).
||FL-411 is a novel small-molecule inhibitor of BRD4, induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction and activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells.
||CLK inhibitor T3
||CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively.
||GW274150 is a potent and highly selective inhibitor of iNOS with IC50 of 1.4 uM, displays >200 fold selectivity over eNOS and nNOS (IC50>100 uM).
||BAY 299 is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1 and the second bromodomain of TAF1 with IC50 of 6 nM and 13 nM, respectively.
||XMU-MP-2 is a potent and selective BRK/PTK6 (breast tumor kinase) inhibitor with biochemical IC50 of 3.2 nM.
||Merimepodib (VX-497, VI-21497, MMPD) is a potent, selective, reversible, uncompetitive IMPDH inhibitor with broad-spectrum antiviral activity.
||A novel FTY720 analog that acts as PP2A activator, disrupts the SET/PP2A interaction devoid of immunosuppressive effects leads to the reactivation of PP2A.
||GNE-049 is a potent, selective, orally available inhibitor of CBP/p300 bromodomain with biochemical IC50 of 1.1/2.3 nM, respectively.
||A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM.
||A selctive small molecule inhibitor of the transcription factor GATA-binding protein 2 (GATA2).
||AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.
||A potent, selective and orally active BRPF1 bromodomain inhibitor with IC50 of 7.9 nM, with excellent selectivity over nonclass IV BRDs.
||β-catenin-IN-11a is a β-catenin/CD44/Nanog axis inhibitor, docks into the β-catenin allosteric site and interferes β-catenin/TCF-4 complex.
||TRIM24 inhibitor X
||TRIM24 inhibitor X is a potent TRIM24 bromodomain inhibitor for synthesis dTRIM24.
||NI-57 is a potent inhibitor of the bromodomain of the BRPFs and binds to BRPF1B, BRPF2 and BRPF3 and with KD of 31 nM,108 nM and 408 nM (ITC), respectively.
||iCRT-5 is a selective, cell-permeable β-catenin responsive transcription (CRT) inhibitor with IC50 of 18 nM.
||An non-competitive, allosteric inhibitor of PTP1B with Ki of 0.6 uM for PTP1B1-405.
||NNC 05-2090 HCl
||NNC 05-2090 is a potent selective GABA transporter inhibitor of mGAT2 with Ki of 1.4 uM.
||Dynein2-IN-37 (Ciliobrevin analog 37) is a potent, selective cytoplasmic dynein 2 ATPase activity antagonist with IC50 of 11 uM, shows weak inhibition for dynein 2 (IC50=280 uM).
||SMAP (DT-061, DT061) is an orally bioavailable small molecule activator of PP2A, inhibits KRAS-driven tumor growth.
||Razuprotafib sodium is a potent protein tyrosine phosphatase β(HPTPβ) inhibitor.
||GS-5734 (Remdesivir) is a monophosphoramidate prodrug of adenosine analogue that exhibits antiviral activity against multiple variants of EBOV (EC50=70-140 nM) and other filoviruses (EC50=0.019-1.48 uM) in cell-based assays.
||SMAP-2 (DT-1154) is an orally bioavailable small molecule activator of PP2A, binds to PP2A Aα scaffold subunit and inhibits KRAS-driven tumor growth both in vitro and in vivo.
||P62-mediated mitophagy inducer
||P62-mediated mitophagy inducer (PMI) is a small molecule P62-mediated mitophagy inducer that activates mitophagy without recruiting Parkin or collapsing membrane potential and retains activity in cells devoid of a fully functional PINK1/Parkin pathway.
||LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.
||IACS-7e is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement).
||E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.
||PF-6689840 (PF6689840) is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 54 nM in biochemical assays.
||PF-6683324 (PF6683324) is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 76 nM in biochemical assays.
||A potent AHR (aryl hydrocarbon receptor) agonist that induces degradation of AhR by the ubiquitin-proteasome pathway.
||FICZ is a high affinity aryl hydrocarbon receptor (AhR) agonist with Kd of 70 pM.
||GS-493 is a novel potent, selective SHP2 inhibitor with IC50 of 71±15 nM in enzyme assay.
||A potent, selective inhibitor of the first bromodomain of BET (BRD4-BD1) with Ki of 77 nM.
||BI 894999 is a novel potent, selective BET inhibitor with IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively.
||INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.
||LLY-2707 (LLY 2707, LLY2707) is a novel potent, selective, nonsteroidal glucocorticoid receptor antagonist with Ki of 2.13 nM.
||A potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor for treatment for type 2 diabetes.
||A potent, orally available, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 12 and 63 nM, respectively.
||INH154 is a novel small molecules disrupting Hec1/Nek2 interaction, inhibits HeLa and MDA-MB-468 cancer cells growth with IC50 of 0.20 and 0.12 uM, respectively.
||GPR39 modulator 7
||GPR39 modulator 7 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=20 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.
||GPR39 modulator 3
||GPR39 modulator 3 is a Hedgehog pathway inhibitor that has high cellular potency (EC50=5 nM) in the reporter gene assay, activates the orphan receptor GPR39 and potently reduces of Gli1 and Ptch1 mRNA levels.
||A GABA transport inhibitor with IC50 of 5, 21, 388 and 140 uM for hGAT-3, rGAT-2, hGAT-1 and BGT-1, respectively.
||Rostafuroxin (PST2238) is potent, selective, orally active Na-K-ATPase inhibitor, displaces 3H ouabain from dog kidney Na+,K+-ATPase with IC50 of 1.5 nM.
||A potent, selective serine/threonine protein phosphatase 2A (PP2A) inhibitor with IC50 of 0.4 uM.
||A highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL.
||A potent, selective glucocorticoid receptor (GR) antagonist with Ki of 7.2 nM in the HepG2 TAT assay.
||A potent, dual TAK1/p38a inhibitor with IC50 of 156/186 nM respectively, with good kinome selectivity against 50 representative kinases.
||Leucettamine B is a potent inhibitor of CLK1 (IC50=15 nM), Dyrk1A (IC50=40 nM), and Dyrk2 (IC50=35 nM) and a moderate inhibitor of CLK3 (IC50=4.5 uM).
||NNC-711 is a potent and selective inhibitor of GABA uptake by GAT-1 with IC50 of 0.04 uM.
||SBI-425 is a potent, selective, orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 16 nM, shows high selectivity over other alkaline phosphatases including IAP and PLAP.
||TD-139 (TD139) is a highly potent, selecitve inhibitor of Galectin-3 (Gal-3) carbohydrate binding domain with Ki of 14 nM.
||BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM).
||A potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).
||BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8 nM.
||A potent SHIP2 inhibitor that enhances in vitro insulin signaling through the Akt pathway more efficiently than AS1949490, and ameliorates abnormal glucose metabolism in diabetic (db/db) mice.
||Factor D inhibitor 7
||Factor D inhibitor 7 is a potent and selective, orally bioavailable inhibitor of Factor D with IC50 of 50 nM.
||TC-2153 is a specific, small moelcule inhibitor of neuron-specific tyrosine phosphatase STEP with IC50 of 24.6 nM.
||MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.
||FAS-IN-1 is a potent inhibitor of fatty acid synthase (FAS) wtih IC50 of 10 nM.
||A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine.
||Ciliobrevin D is a cell-permeable, reversible, specific inhibitor of cytoplasmic dynein, blocks dynein-dependent microtubule gliding and ATPase activity while sparing kinesin dependent cellular trafficking.
||A potent and selective NIMA-related Kinase 2 (NEK2) inhibitor with IC50 of 22 nM, >200-fold selectivity over Plk1, Mps1, Aurora A and CDK2.
||TAK1-IN-1 is a potent, selective, Type I (ATP-competitive, DFG-in) TAK1 inhibitor with Kd of 59 nM, a thienopyrimidine scaffold that serves as a good starting point for medicinal chemistry.
||A potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.
||A selective, potent and reversible nitrocatechol-type inhibitor of catechol-O-methyltransferase (COMT) for treatment of Parkinson's disease.
||BRK inhibitor P21d
||BRK inhibitor P21d is a potent, selective, cell permeable inhibitor of breast tumor kinase (Brk, PTK6) with IC50 of 30 nM, shows no inhibitory activity against Aurora B and Lck (IC50>20 uM).
||A potent, small molecule Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=13.48 nM K562 cells).
||A potent, next-generation modulator of cereblon E3 ubiquitin ligase with IC50 of 60 nM.
||A novel potent, selective, orally available DPP-4 inhibitor with IC50 of 9 nM.
||NQ301 (CD45 inhibitor 211, Compound 211) is a potent antithrombotic agent that inhibits thromboxane A2 receptor and synthase activity, also is a potent, selective inhibitor of CD45 tyrosine phosphatase with IC50 of 200 nM, >100-fold selectivity over other related PTPs (LAR, PTP1B, PTP-σ, SHP-1 and MKPX).
||BI-99179 is a potent and selective inhibitor of type I fatty acid synthase (FAS) with IC50 of 79 nM.
||A potent and efficacious pregnane X receptor (PXR) activator with EC50 of 200 and 700 nM for human and rabbit PXR.
||Velcalcetide (AMG-416, Velcalcetide, Etelcalcetide, KAI-4169) is a potent, peptide agonist of CaSR, dose-dependenty increases IP1 accumulation with EC50 of 25 uM in cell based assays.
||A water-soluble prodrug of triptolide that is highly effective in reducing pancreatic tumor growth and spread, and improving survival.
||PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.
||AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1).
||A potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor.
||A small-molecule, allosteric inhibitor of DUSP6 (dual-specificity phosphatase 6) with IC50 of 12.3 uM.
||BRPF1B TRIM24-IN-34 is a selective BRPF1B/TRIM24 dual inhibitor that binds with KD of 137 and 222 nM, respectively.
||Siponimod (BAF312) is a potent, selective S1P1/S1P5 receptor modulator with EC50 of 0.39/0.0.98 nM, >1,000-fold selectivity over S1P2/3/4.
||ML197 is a potent, selective small molecule inhibitor of Cdc2-like kinases (CLK) and DYRK with IC50 of 96/40/206 nM for CLK1/CLK4/Dyrk1A, respectively.
||A potent, long acting, reversible and competitive DPP-4 inhibitor with IC50 of 0.9 nM.
||Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM.
||A potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2.
||Rivipansel sodium (GMI-1070, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.
||DBPR108 is a potent, selective, orally bioavailable and long-acting inhibitor of DPP4 with IC50 of 15 nM, >3,000-fold selectivity over DPP8, DPP9, FAP and DPP-II.
||ZL-006 (ZL 006, ZL006) is a brain penetrant small molecule inhibitor of PSD-95/nNOS interaction that prevents glutamate-induced excitotoxicity and cerebral ischemic damage in vivo.
||ZTM000990 is a small-molecule antagonist of the oncogenic Tcf4/β-catenin protein complex with IC50 of 0.64 uM.
||WZ-4-49-8 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 67 nM.
||CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.
||CI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.
||GRL-0617 is a potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 0.6 uM, Ki of 0.49 uM.
||A potent, noncovalent SARS-CoV papain-like protease (PLpro) inhibitor with IC50 of 2.6 uM.
||BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40 nM (inhibition of hC3a induced Ca2+ release on human macrophages).
||PF-04191834 (PF-4191834) is a potent, non‐iron chelating, non‐redox, selective and competitive inhibitor of 5-lipoxygenase (5‐LO) with Ki of 10 nM.
||A homoisoflavanone found in Caesalpinia sappan, a potent, selective IMPDH2 inhibitor that covalently binds to Cys140 with Kd of 3.944 nM, almost 10 times lower than the Kd of binding to IMPDH1.
||A potent ubiquitin E3 ligase HECTD2 inhibitor that specificly disrupts the HECTD2/PIAS1 interaction with IC50 of 5 nM.
||A potent, selective inhibitor of protein phosphatase 2A (PP2A) with IC50 of 0.04 nM.
||Razuprotafib is a potent protein tyrosine phosphatase β (HPTPβ) inhibitor.
||PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.
||A small molecule TAAR1 agonist and β adrenoreceptor agonist that stimulates β1 and β2 adrenergic receptors.
||rac Pterosin B
||rac Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.
||A potent RIG-I-like receptor (RLR) agonist that triggers IRF3-dependent innate immune antiviral genes and IFN-β expression.
||Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.
||YKL-05-099 (YKL 05-099) is a novel potent, selective pan-SIK inhibitor with IC50 of 10, 40 and 30 nM for SIK1, 2 and 3, respectively.
||A small-molecule MAVS-dependent IRF3 agonist that shows antiviral activity against Flaviviridae, Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (RSVs, Nipah virus).
||ARN-3236 is a novel potent, selective, and orally active SIK2 inhibitor with IC50 of <1 nM.
||MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.
||A potent, orally bioavailable inhibitor of S-nitrosoglutathione reductase (GSNOR) and CFTR
||A highly potent, selective and orally bioavailable trace amine-associated receptor 1 (TRRA1) partial agonist with EC50 of 17 nM, >1,000-fold selectivity over human adrenergic α2A receptor.
||A potent and reversible S-Nitrosoglutathione reductase (GSNOR) inhibitor with IC50 of 20 nM.
||A potent, selective TAAR1 agonist with Ki of 1.9, 2.7, 31 and 24 nM for mouse, rat, cynomolgus monkey and human TAAR1 stably expressed in HEK293 cells.
||A potent and selective TAAR1 partial agonist with Ki of 0.5, 1.0, 6.8 and 2.6 nM for mouse, rat, human and monkey TAAR1, respectively.
||A potent, selective, orally active TAAR1 partial agonist with Ki of 6 nM, EC50 of 23 nM (hTAAR1), 140-fold selectivity over β2 adrenergic receptors.
||A novel anti-fibrotic agent that prevents TGF-beta-stimulated production of collagen in cultured renal mesangial cells (55-70% inhibition at 30 uM).
||A potent nuclear receptor TR3 (Nur77)-specific targeting compound that can induce melanoma autophagy through a mitochondrial signaling pathway.
||BMS-986202 (BMS-986202, AM-152) is a potent, selective, orally available antagonist of the Lysophosphatidic Acid 1 Receptor (LPA1 receptor) with IC50 of 18 and 9 nM in calcium mobilisation and β-arrestin assays; fully inhibits the response to LPA in calcium mobilisation, β-arrestin, cAMP, GTPγS and RhoA functional assays.
||ABC99 is a potent, selective inhibitor of the Wnt-deacylating enzyme serine hydrolase NOTUM with IC50 of 13 nM, shows excellent selectivity across the serine hydrolase family.
||SGL5213 is a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor with IC50 of 29 nM/20 nM for hSGLT1/hSGLT2.
||JBJ-16-111 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E.
||BAY-850 is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay
||A first-in-class, small molecule protein-protein inhibitor of the interaction between the E1 and E2 proteins of HPV types 6 and 11
||A potent, first-in-class, oral small-molecule agent for the treatment of inflammatory bowel diseases.
||PH-46A N-Methyl-D-Glucamine salt
||A potent, first-in-class, oral small-molecule agent for the treatment of inflammatory bowel diseases.
||A potent, specific and orally bioavailable soluble epoxide hydrolase (sEH) inhibitor with IC50 of 1.3 nM
||A novel SirReal-based PROTAC that induces isotype-selective Sirt2 degradation (IC50=0.25 uM).
||A potent BET bromodomian inhibitor with IC50 of 3-7 nM for BRD2/3/4 BD1 and BD2.
||A PEG3 linker for PROTAC.
||VHL Ligand 3
||A VHL ligand for PROTAC.
||VH-032 (VHL ligand 1) is a VHL ligand for PROTAC and potent, small molecule inhibitor of the VHL/HIF-1α interaction with Kd of 185 nM.
||A VHL ligand for PROTAC.
||VHL Ligand 4
||A VHL ligand for PROTAC.
||A PEG4 linker for PROTAC.
||A PEG2 linker for PROTAC.
||CC-885 (CC 885, CC885) is a novel E3 ligase cereblon (CRBN) modulator with potent anti-tumour activity mediated through the degradation of GSPT1
||dBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex
||A novel potent, slow tight binding LPA1 receptor antagonist with IC50 of 86 nM, Kd of 0.34 nM
||A potent adenosine transport activity of ENT-1 with IC50 of 26.9 nM
||A potent chelator of iron that arrests late stages of cytokinesis by blocking the physical process of constriction in dividing cells
||The first selective, cell-permeable inhibitor of GAG sulfotransferases with IC50 of 2.0-2.5 uM
||A novel P-selectin inhibitor that directly binds to P-selectin
||A cell-permeable FKBP ligand that is designed to protect an otherwise unstable protein domain from degradation
||An isoquinoline carboxamide that binds selectively to PBR (TSPO) with Ki of 3.1 nM in cerebellum, 4.1 nM in spinal cord
||A cell permeable, mechanistically unique inhibitor of protein sumoylation
||A potent, selective ligand for the mitochondrial translocator protein 18kDa (TSPO/PBR)
||An activator of the Wnt/β-catenin signaling pathway that targets the DIX domain of Axin
||A small molecule ANXA7 GTPase activity inhibitor, induces mouse ESCs differentiation to VECs
||PF-00446687 hydrochloride (PF-446687) is a potent, selective melanocortin-4 receptor (MC4R) agonist with EC50 of 12 nM
||PF-00446687(PF-446687) is a potent, selective melanocortin-4 receptor (MC4R) agonist with EC50 of 12 nM
||A potent, selective, full agonist of human and murine MC1R with EC50 of 16.8 and 11.6 nM, respectively
||CK-2127107(CK-107, Reldesemtiv) is a novel orally active fast skeletal troponin activator, selectively activates fast skeletal myofibrils with EC50 of 3.4 uM
||A potent inhibitor of the mRNA decapping scavenger enzyme (DcpS) with IC50 of 0.11 nM
||A potent, selective CRAC channel Orai1 blocker with IC50 of 3 uM
||CCT-367766 (CCT367766) is a novel heterobifunctional PROTAC that binds and degrades the putative transcription factor regulator Pirin in cells.
||A potent, selective, orally available GPR40 agonist with Ki of 15 nM, β-arrestin EC50 of 108 nM
||GPR30 inhibitor G15
||G-15 (GPR30 inhibitor G15, G15) is a potent, selective GPER/GPR30 antagonist with Ki of 20 nM
||GPR30 inhibitor G36
||A potent, selective, cell-permeable GPER/GPR30 antagonist that inhibits activation by either 17β-estradiol or the GPER-selective agonist G-1 with IC50 of 112 nM and 165 nM, respectively
||GPR30 inhibitor G1
||A potent and selective GPER/GPR30 agonist with Ki of 11 nM, EC50 of 2 nM
||A potent, highly selective, orally active MDM2-p53 interaction inhibitor with IC50 of 4 nM
||DS-3032b is a potent, selective, orally available MDM2-p53 inhibitor with potential antineoplastic activity
||A potent, selective, and orally active p53-MDM2 antagonist with IC50 of 6 nM
||A potent, selective, and orally active p53-MDM2 antagonist with IC50 of 7 nM
||GNE-781 is a potent, selective, non-CNS penetrant, orally active CBP/p300 bromodomain inhibitor with IC50 of 0.94/1.2 nM in TR-FRET assays
||A novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM
||GB-88 is a selective, orally available PAR2 antagonist that inhibits PAR2 activated Ca(2+) release with IC50 of 2 uM
||GB-110 is a potent, non-peptidic agonist of PAR2 that selectively induces PAR2-mediated intracellular Ca(2+) release in HT29 cells with EC50 of 0.28 uM
||AZ-8838 (AZ8838) is a potent, and selective PAR2 antagonist with Kd of 125 nM
||THAL-SNS-032 is a novel CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN)
||UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2
||A potent glutaminyl cyclase (QC) inhibitor that inhibits human, rat, and mouse QC with Ki of 20-65 nM
||A hit compound that inhibits the proliferation of human peripheral blood T cells stimulated with anti-CD3 with IC50 of <10 nM, inhibits TCR-Nck interaction.
||APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively
||APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively
||A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 5.3 uM in ELISA assay
||A small molecule inhibitor of MDM2-p53 protein-protein interaction with IC50 of 16 uM.
||A small molecule inhibitor of HDM2-p53 interaction with FP IC50 of 0.7 uM
||A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.4 nM), cellular potency (SJSA-1 EdU IC50=25 nM), and favorable pharmacokinetic properties
||A potent, dual MDM2/MDMX-p53 interaction inhibitor with IC50 of 17 and 24 nM, respectively
||A novel specific MDM2 inhibitor that promotes MDM2 auto-ubiquitination and degradation
||A potent and orally active p53-MDM2 interaction inhibitor with IC50 of 2.4 nM
||Cotylimide-VI (CTL-VI) is a small molecule that perturbs plant hormone strigolactone accumulation and inhibits hypocotyl growth.
||BIO 8898 is a synthetic, CD40-CD154 co-stimulatory interaction inhibitor that inhibits the TNF family cytokine CD40L binding to CD40-Ig with a potency of IC50=25 uM.
||UK-396082 is a potent and selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (activated TAFI.
||AA147是转录因子ATF6的特异性小分子激动剂，其激活ATF6并影响干细胞的分化。AA147 is a specific, small molecule agonist of transcription factor ATF6, activates ATF6 and influences differentiation of stem cells.
||Spliceostatin A is a methylated derivative of FR-901464 that inhibits pre-mRNA splicing.
||A steroid hormone with a weak androgenic effect, and an intermediate/prohormone of 11-ketotestosterone.
||A novel potent, irreversible Myeloperoxidase (MPO) inhibitor with IC50 of 44 nM.
||VPC-18005 (VPC18005) is a novel small molecule ERG (ETS-related gene) antagonist that inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, disrupts the ERG binding to DNA (Kd=250 uM).
||6-Fluorescein isothiocyanate(6-FITC) is a derivative of fluorescein used in wide-ranging applications including flow cytometry.
||The single isomer, 6-FAM, contains a carboxylic acid that can be used to react with primary amines via carbodiimide activation of the carboxylic acid. Fluorescein is the most common fluorescent derivatization reagent for labeling biomolecules. In addition to its relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility, fluorescein has an excitation maximum that closely matches the 488 nm spectral line of the argon-ion laser.
||RH01687 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.
||RH01386 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.
||Naxillin is the first non-auxin-like molecule that promotes root branching, activates a subset of auxin-induced transcripts, including AUX/IAA, SAUR and PIN families.
||4-CPPC is the first reversible and selective inhibitor of pro-inflammatory protein macrophage migration inhibitory factor-2 (MIF-2) with Ki of 33 uM, 13-fold selectivity for human MIF-2 versus human MIF-1.
||7DG (7-Desacetoxy-6,7-dehydrogedunin) is a selective inhibitor of protein kinase R (PKR) that directly interact with the C-terminal of PKR.
||Teglicar (ST-1326) is a potent, selective and reversible inhibitor of liver carnitine palmitoyl-transferase 1 (L-CPT1) with IC50 of 0.68 uM, Ki of 0.36 uM.
||Laquinimod (ABR-215062) is an immunoregulator derived from Linomide, has been shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE).
||A FDA approved topical corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery.
||JI051(JI-051) is a specific compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.
||KSC-34 (PDIA1 inhibitor KSC-34) is a potent, selective protein disulfide isomerase A1 (PDIA1) inhibitor, 30-fold selectivity for the A-site over the A' site.
||Olesoxime (TRO 19622) is a cholesterol-like compound that binds directly to two components of the mitochondrial permeability transition pore: the voltage-dependent anion channel and TSPO (or PBR).
||K-604 is a potent, selective and competitive ACAT-1 inhibitor with IC50 of 0.45 uM for human ACAT-1, displays 229-fold selectivity over ACAT-2.
||A substance being developed for the control of weeds such as watergrass in rice.
||A tailored WOBE437-derived diazirine-containing photoaffinity probe that irreversibly blocks membrane transport of both endocannabinoids.
||A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 2 uM.
||A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 4 uM.
||PNPLA4-IN-1 is a potent, selective, and irreversible PNPLA4 inhibitor with IC50 of 1.8 uM (separated membrane proteome fraction), shows in-cell inhibition of PNPLA4 with IC50 of 11.7 uM.
||PF-6808472 (XO44) is a sulfonyl fluoride chemical probe that covalently labels a broad swath of the intracellular kinome with high efficiency.
||Sudemycin K is a synthetic antitumor splicing inhibitor with IC50 of 15 nM (MCL1 alternative splicing regulation), shows cytotoxicity in HeLa cells with IC50 of 2.3 nM.
||A potent, relatively selective G protein-coupled receptor kinase GRK2 inhibitor with IC50 of 280 nM.
||MN58b is a potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.4 uM, >30-fold selectivity over ChoKβ and does not affect MAPKs, PI3Ks, and other enzymes involved in the regulation of phospholipid metabolism.
||JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.
||Lin28-IN-1 is a small-molecule inhibitor of the Lin28/let-7 interaction with IC50 of 4.03 uM.
||PAT-1251 (PAT 1251, PAT1251) is a potent, selective and orally bioavailable lysyl oxidase-like 2 (LOXL2) inhibitor with IC50 of 0.71 uM in human whole blood assays, with high selectivity over LOX (400-fold) and other amine oxidases.
||JHU-083 is an orally available prodrug of the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (DON), blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress.
||YPC-22026, a metabolically stable derivative of YPC-21661, is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143), inhibits the binding of ZNF143 to DNA.
||AKR1C3 inhibitor KV-37
||AKR1C3 inhibitor KV-37 is a potent, isoform selective and metabolically stable inhibitor of Aldo-keto reductase 1C3 (AKR1C3) with IC50 of 66 nM, displays 109-fold selectivity over AKR1C2.
||A highly potent and selective GRK2 inhibitor with IC50 of 18 nM.
||TES-1025 (TES1025) is a potent, selective inhibitor of human ACMSD (α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase) with IC50 of 13 nM, increases NAD+ levels in cellular systems.
||EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines.
||ML404 is a small molecule inhibitor of mtPTP, inhibits mitochondrial swelling with EC50 of 4.9 nM, shows no effect on mitochondrial coupling at >100 uM.
||H3B-8800 is an orally available splicing modulator that targets spliceosome SF3b complex containing either WT
or mutant SF3B1 (binding IC50 of 0.3-2 nM).
||A sulfobutylether β-cyclodextrin derivative, it is an excipient or a formulating agent used to increase the solubility of poorly soluble drugs. .
||CU-3 (DGKα inhibitor CU-3) is a is a novel potent, selective diacylglycerol kinase α (DGKα) inhibitor with IC50 of 0.6 uM, targets the catalytic region, but not the regulatory region.
||A derivative of the antifungal drug itraconazole (ITA) as an inhibitor of MFB cell fate in resident fibroblasts derived from multiple murine and human tissues.
||KG-548 is an ARNT/TACC3 disruptor (IC50=25 uM) that selectively bind within the ARNT PAS (Per-ARNT-Sim) domain that recruits TACC3.
||CD38 inhibitor 78c
||CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.
||Hemicholinium-3 (HC-3) is a competitive, small molecule inhibitor of choline kinase (ChoK) with ex vivo IC50 of 500 uM, also bolcks the sodium and chloride-dependent transport system and affects choline acetyltransferase.
||DS-2330 is a phosphorous lowering agent for treating hyperphosphatemia in chronic kidney disease.
||JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.
||ARN726 is a potent, selective, orally bioavailable N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 63 nM (r-NAAA) and 27 nM (h-NAAA).
||Hemoglobin modulator TD-1 (TD-1) is a novel allosteric effector of hemoglobin that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
||IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain.
||BMT-090605 (BMT 090605, BMT090605) is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 0.6 nM.
||BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM.
||SB-204990 is the cell-penetrant, orally active gamma-lactone prodrug of the potent ATP citrate-lyase (ACLY) inhibitor SB-201076.
||NCT-502 is a small molecule 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3.7 uM) that reduces the production of glucose-derived serine in cells and suppress the growth of PHGDH-dependent cancer cells.
||Fulacimstat (BAY 1142524, BAY1142524) is a potent, orally available chymase inhibitor with IC50 of 4 nM and 3 nM for human and hamster chymase enzyme, respectively.
||LP-935509 is a potent, selective and brain-penetrant adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 of 3.3 nM.
||An novel anti-inflammatory agent.
||A potent, highly selective and irreversible inhibitor of myeloperoxidase (MPO) with Kinact/KI of 116000 M-1s-1.
||Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), produces ROS, and induces cytotoxicity in cancer cells in an NQO1-dependent manner.
||A potent, CNS-active Glucosylceramide synthase (GCS) inhibitor with IC50 of 27 nM.
||A small molecule inhibitor of clathrin terminal domain and inhibits clathrin-mediated endocytosis.
||A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM).
||PE859 is a novel, orally active tau aggregation inhibitor that inhibits the heparin-induced aggregation of both 3RMBD and full length tau with IC50 of 0.81 uM and 2.23 uM, respectively.
||PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication.
||Setafrastat is a small molecule hair growth stimulator.
||ZINC-3573 racemate is a potent, selective agonist of the atypical opioid receptor MRGPRX2 (EC50=3 uM), showing little activity against 315 other GPCRs and 97 representative kinases.
||ARN077 is the first potent, selective N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 7 nM on both rat NAAA and human NAAA.
||trans Ned-19 is a cell-permeant chemical probe for the Ca(2+)-releasing second messenger NAADP, blocks NAADP signaling (IC50=6 nM, inhibition of Ca2+ release).
||A potent, irreversible inhibitor of human tissue transglutaminase (hTG2).
||A potent, irreversible inhibitor of human tissue transglutaminase (hTG2).
||ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.
||A potent, selective inhibitor of clathrin-independent endocytosis with IC50 of 18 uM (inhibition of clathrin TD-amphiphysin B/C complex formation).
||A homogenous mixture of compound that is used to stain amyloid plaques, binds to amyloid fibrils but not monomers and gives a distinct increase in fluorescence emission.
||RU-505 is an effective inhibitor of the Aβ42-fibrinogen interaction with IC50 of 2.72 uM in FP assays.
||Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor.
||TMP-153 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor with IC50 of 5-10 nM for the hepatic and intestinal ACAT from various animals.
||N-acetyl lysyltyrosylcysteine amide
||N-acetyl lysyltyrosylcysteine amide (KYC) is a potent, tripeptide inhibitor of myeloperoxidase (MPO), inhibits MPO-mediated hypochlorous acid (HOCl) formation (IC50=7 uM) and nitration/oxidation of LDL.
||ACT-389949 is a novel potent and selective formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) agonist with EC50 of 3 nM, shows potential for the treatment of inflammatory disorders.
||A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.
||EXEL-0346 (EXEL0346) is a novel potent, orally active Glucosylceramide synthase (GCS) inhibitor with IC50 of 2 nM.
||TRX-0237 Methylate (LMTX) is a Tau aggregation inhibitor (TAI) with Ki of 0.12 uM for intracellular TAI activity.
||GNX-865 is a potent mitochondrial permeability transition pore (mPTP) inhibitor with EC50 of 105 uM (mitochondrial swelling).
||An orally active pterocarpanquinone that exhibits antitumoral and antileishmanial activity both in vitro and in vivo.
||A small molecule inhibitor of diacylglycerol kinase (DGK) with IC50 of 0.01-10 uM in isolated platelet membranes and in intact platelets.
||Sudemycin E is an alternative splicing inhibitor that binds to the U2 small nuclear ribonucleoprotein (snRNP) component SF3B1, causes a rapid change in alternative pre-messenger RNA splicing.
||Nexinhib 20 is a novel small molecule neutrophil exocytosis inhibitor (IC50=0.33 uM) that specifically inhibits Rab27a-JFC1 binding (IC50=2.6 uM) but does not interfere with the interaction of other Rab GTPases and effectors.
||Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.
||Emixustat (ACU-4429) is a first in class small-molecule inhibitor of the visual cycle isomerase (RPE65) with IC50 of 4.4 nM.
||BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM.
||Z62954982 is a potent, specific Rac1 inhibitor, reduces the intracellular levels of Rac1-GTP in a concentration-dependent manner with IC50 of 12 uM, 4 times more effective than NSC23766 (IC50=50 uM).
||A specific, membrane-permeable inhibitor of Gq signaling.
||ML359 is a small molecule, specific inhibitor of Protein disulfide isomerase (PDI) with IC50 of 250 nM.
||CXL017 is a small molecule that has selective cytotoxicity toward MDR cancer cell lines in vitro, through inhibition of the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) with IC50 of 15 uM.
||5S rRNA modificator 2
||A novel chemical probe that enable selective 2’-hydroxyl acylation for accurate RNA structural analysis in living cells.
||ALZ-801 is an orally available, valine-conjugated prodrug of tramiprosate, a small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor for the treatment of Alzheimer's disease.
||A potent, irreversible and cell permeable inhibitor of tissue transglutaminase with IC50 of 20 nM.
||A potent, specific, competitive inhibitor of choline kinase-α (Chok-α) by targeting the choline binding site.
||Sephin1(IFB-088) is a selecitive PPP1R15A inhibitor, but not the related regulatory phosphatase PPP1R15B.
||A novel small-molecule arenaviruse inhibitor that exhibits strong anti-LCMV activity (IC50<1 uM) without cell toxicity
||Dihydromunduletone is a rotenoid derivative that selectively inhibits GPR56 (IC50=21 uM) and GPR114/ADGRG5, but not GPR110 or Class A GPCRs
||PF-06678419 (PF06678419) is a potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.44 uM
||A potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.41 uM
||GWJ-A-23 (GWJ-23, GWJ23) is a potent, selective autotaxin inhibitor with Ki of 18 nM, an analog of the known ATX inhibitor S32826 and has improved aqueous solubility compared with the parent compound
||A novel potent and selective agonist of GPR84 that induces calcium response with EC50 of 0.213 uM
||A novel antiprion compound with EC50 of 68 nM, significantly increases monoglycosylated/diglycosylated PrPSc.
||A novel potent, selective IRAK4 inhibitor with IC50 of 51 nM
||SNIPER(ABL)-062 is a novel, potent SNIPER molecule that tethers BCR-ABL inhibitor to a ligand of IAP, causes potent BCR-ABL degradation
||A novel potent, selective Sirt2 inhibitor with IC50 of 0.118 uM
||A novel potent, selective Sirt2 inhibitor with IC50 of 3.745 uM
||GPR120 agonist 4x
||A potent, selective, orally bioavailable GPR120 agonist with EC50 of 42 nM in calcium flux assays
||A cell permeable CBP bromodomain inhibitor with Kd of 19 uM
||The first potent, selective inhibitor for PTPRZ (protein tyrosine phosphatase receptor-type Z) with IC50 of 0.4 uM against human Z-ICR-catalyzed hydrolysis
||PAT-505 (PAT 505, PAT505) is a potent, selective, noncompetitive, and orally active autotaxin inhibitor with IC50 of 2.0 nM against the lysoPLD activity of human ATX
||PAT-048 (PAT048) is a potent, selective, noncompetitive autotaxin inhibitor with IC50 of 1.1 nM against the lysoPLD activity of human ATX
||A-1048400(A 1048400) is a novel potent, selective, orally active N-type and T-type calcium channel blocker with IC50 of 1.4 and 1.2 uM, respectively
||BETd-260 (ZBC260, BETd260) is a novel PROTAC BET degrader that tether HJB97 to a ligand for the E3 ubiquitin ligase VHL
||BETd-260 trifluoroacetate (ZBC260, BETd 260 TFA) is a novel PROTAC BET degrader that tether HJB97 to a ligand for the E3 ubiquitin ligase VHL
||A highly potent, selective mutant p53 (R175H, R249S, R273H, R273C) reactivator
||LY2922470 (LY-2922470) is a potent, selective, orally available GPR40 agonist with EC50 of 7 nM
||A potent, selective, orally available GPR40 agonist with EC50 of 9 nM
||A potent, selective, orally available GPR40 agonist with EC50 of 8 nM
||TBK1 PROTAC 1
||A novel potent, selective TBK1 PROTAC with DC50 of 12 nM, selectively degrades TBK1 with excellent selectivity against a related kinase IKKε
||A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM
||A potent, selective S1P3 antagonist with Ki of 0.25 nM
||A homo-PROTAC, bivalent small-molecule dimerizer of the VHL E3 ubiquitin ligase to induce self-degradation.
||A novel brain penetrant antiprion compound with EC50 of 57 nM, prevents both PrP(Sc) accumulation and astrocytic gliosis in the cerebrum
||A cell permeable CBP bromodomain inhibitor with Kd of 19 uM
||SALL4 peptide FFW
||SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD (nucleosome remodeling deacetylase) interaction with target affinity of 23 nM
||RTI-13951-33 is a potent, selective, brain-penetrant agonist of the orphan receptor GPR88 with EC50 of 25 nM in in vitro cAMP functional assay
||MS645 (MS-645) is a novel, bivalent bromodomain (BRD) inhibitor with Ki of 18.4 nM for tandem BD1-BD2 (BRD4 BD1/BD2 ), shows12- to 28-fold gain in affinity for binding to the tandem BD1-BD2 over the single BD1 or BD2
||BTK PROTAC 9
||BTK PROTAC 9 is a novel potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK
||BTK PROTAC 10
||BTK PROTAC 10 is a novel potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells
||CR6086 (CR-6086) is a potent, selective prostaglandin E2 receptor 4 (EP4) antagonist with Ki of 16.6 nM (hEP4 receptor), inhibits PGE2-stimulated cAMP production with IC50 of 22 nM
||CDK12 inhibitor 2
||CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9
||MAI-400 (MAI400) is a novel peptide inhibitor of APC-Asef interaction with Kd of 12 nM and IC50 of 0.25 uM
||RORγt inverse agonist 32
||RORγt inverse agonist 32 is a potent, orally bioavailable inverse agonist of RORγt with IC50 of 9 nM in SPA binding assays
||CCR6 inhibitor 35
||CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6)
||Cyclophilin inhibitor C31
||Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction
||RAS inhibitor Abd-7
||RAS inhibitor Abd-7 is a potent RAS-binding compound (Kd=51 nM) that interacts with RAS in cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signalling
||AM9405 (AM-9405) is novel potent, peripherally active cannabinoid type 1 (CB1) and 5-HT3 receptor agonist, inhibits the EFS-induced twitch contraction of the ileum and the colon with IC50 of 0.076 and 45.71 nM, respectively
||KRAS inhibitor Cmpd2
||KRAS inhibitor Cmpd2 is a small-molecule compound that blocks biochemical and cellular functions of KRASG12V with IC50 of 0.8 uM in vitro
||VERU-111 analogue 13f
||VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities
||MB 07811 (MB07811) is an orally bioavailable, liver-targeted prodrug of MB07344, which is a thyroid hormone receptor-beta agonist (TRβ) agonist, efficiently converted to MB07344 by liver microsomes in vivo
||MP-HJ-1b is a novel potent inhibitor of microtubule and tumor cell growth, binds the colchicine pocket at the intra-dimer interface, depolymerizes microtubules and affects spindle formation
||NTCP binder peptide WL4
||NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=42 nM), reduces HBs antigen levels in culture supernatants with IC50 of 0.66 uM
||NTCP binder peptide WD1
||NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=15 nM), reduces HBs antigen levels in culture supernatants
||Brusatol (NSC 172924, (+)-Brusatol) is a quassinoid extracted from Brucea Esters, can inhibit HIF-1 signaling pathway, also is a potent Nrf2 inhibitor
||GSK3004774 (GSK-3004774) is a potent, nonabsorbable, gastrointestinally-restricted agonist of calcium-sensing receptor (CaSR) with pEC50 of 7.3.
||mutant EGFR inhibitor B30
||mutant EGFR inhibitor B30 is a potent, selective, next-generation EGFR mutants inhibitor with IC50 of 1.1 and 7.2 nM for EGFRL858R and EGFRL858R/T790M/C797S, respectively
||WY-135 (WY135) is a novel potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively
||MF-094 (MF094) is a potent, highly selective inhibitor of ubiquitin specific protease 30 (USP30) with IC50 of 0.12 uM, demonstrates <30% inhibitory activity for a panel of 22 USPs assays at 10 uM
||A12B4C3 (hPNKP inhibitor A12B4C3) is a specific, noncompetitive inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase (hPNKP) with IC50 of 60 nM, displays no inhibition of calcineurin and protein phosphatase-1 or APTX.
||VXc-486 (VXc486) is a novel inhibitor of gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro with MICs of 0.03-0.30 μg/ml and 0.08-5.48 μg/ml, respectively
||ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase
||AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity.
||TAK-615 (TAK615) is a potent, selective, negative allosteric modulator (NAM) of the LPA1 receptor, partially inhibits the LPA response with IC50 of 91 nM (60% at 10 uM) in calcium mobilisation assays.
||SAR-100842 (SAR100842) is a potent, selective, orally available antagonist of the Lysophosphatidic Acid 1 Receptor (LPA1 receptor) with IC50 of 31 nM in β-arrestin assays
||LY900009 (LY-900009) is an orally active small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein, inhibits Notch signalling in tumour cell lines and endothelial cells with IC50 of 0.005-20 nM
||NIK inhibitor 4f
||NIK inhibitor 4f is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM, shows an IC50 of 34 nM in NF-κB reporter assays
||UCB9608 (UCB-9608) is a potent, selective, orally bioavailable PI4KIIIβ inhibitor with IC50 of 11 nM
||Tianeptinaline is a class I HDAC-selective, brain penetrant analogue of tianeptine with IC50 of 0.24, 0.12 and 0.155 uM for HDAC1, 2 and 3 respectively, does not inhibit HDAC6
||Tianeptinostat is a class I HDAC inhibitor with IC50 of 28, 33 and 51 nM for HDAC1, 2 and 3, respectively, also inhibits HDAC6 (IC50=1.6 nM) but not HDAC5 (IC50>80 uM)
||HDAC6 degrader 9c
||HDAC6 degrader 9c (dHDAC6 9c) is a bifunctional molecule (dHDAC6) that could selectively degrade HDAC6, by conjugating non-selective HDAC inhibitor to a thalidomide-type E3 ligase ligand
||HAMI3379 (HAMI-3379) is a potent and selective antagonist of cysteinyl leukotriene 2 (CysLT(2)) receptor, inhibits LTD4- and LTC4-induced intracellular calcium mobilization withIC50 of 3.8 nM and 4.4 nM respectively
||MPT0G211 is a novel potent, selective HDAC6 inhibitor with IC50 of 0.291 nM, displays >1,000-fold selectivity over other HDAC isoforms
||UCT943 (UCT-943) is a potent, selective, next generation Plasmodium falciparum PI4K inhibitor with IC50 of 23 nM
||BU09059 is a potent, selective, short-acting kappa-opioid receptor antagonist with Ki of 1.72 nM, displays 15- and 616-fold selectivity over μ- and δ-receptors respectively
||RasGRP3 ligand 96
||RasGRP3 ligand 96 is a potent, selective ligand of Ras guanine-releasing protein 3 (RasGRP3) with Ki of 1.75 nM, showed 73-fold and 45-fold selectivity relative to PKCα and PKCε for in vitro binding activity resepctively
||MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA
||sPLA2-X inhibitor 31
||sPLA2-X inhibitor 31 is a potent, selective secreted phospholipase A2 type X (sPLA2-X) with IC50 of 26 nM, displays 12-fold and 80-fold selectivity over sPLA2-Iia and sPLA2-V, respectively
||MB725 is a small-molecule p53 mutant Y220C stabilizer, induces selective viability reduction in several p53-Y220C cancer cell lines (Huh7 cell IC50=10 uM)
||MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro.
||STING inhibitor C-178
||STING inhibitor C-178 is a covalent, small-molecule inhibitor of STING, blocks palmitoylation (PMA)-induced clustering of STING
||STING inhibitor C-176
||STING inhibitor C-176 (C-176) is a covalent, in vivo-active, small-molecule inhibitor of STING, attenuates STING-associated autoinflammatory disease in mice.
||STING inhibitor H-151
||STING inhibitor H-151 (H-151) is a highly potent, selective, covalent small-molecule antagonist of STING that has noteworthy inhibitory activity both in human cells and in vivo.
||S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM
||S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM, inhibits 5-oxo-ETE-induced calcium mobilization in human neutrophils.
||TLR7 and 8 modulator 31
||TLR7 and 8 modulator 31 is a potent, orally active, dual TLR7 and 8 agonist with LEC values of 0.15 and 0.16 uM, respectively
||SW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
||SW076956 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
||JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM)
||Flavokawain B is a natural chalcone that can induce apoptosis in androgen receptor-negative, hormone-refractory prostate cancer cell lines (IC50=3-50 uM), via up-regulation of death-receptor 5 and Bim expression
||CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay
||EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay
||CPSI-1306 (CPSI1306) is an orally available small-molecule MIF antagonist, protects against UVB-induced squamous cell carcinoma, reduces the severity of animal model of multiple sclerosis.
||SGN-2FF is an orally bioavailable small molecule inhibitor of glycoprotein fucosylation, demonstrates encouraging preclinical antitumor activity in mouse models
||LTX-401 (LTX401) is an oncolytic amino acid derivative with potential immunogenic properties, selectively destroys the structure of the Golgi apparatus
||LTX-401 dihydrochloride (LTX401) is an oncolytic amino acid derivative with potential immunogenic properties, selectively destroys the structure of the Golgi apparatus
||Tucidinostat (Chidamide, HBI-8000, CS055) is a novel histone deacetylase (HDAC) inhibitor with IC50 of 95/160/67/733/78/432 nM for HDAC1/2/3/8/10/11, respectively
||Azosemide (Azosemidum) is a potent Na-K-Cl Cotransporter NKCC1 with IC50 of 0.246 and 0.197 uM for hNKCC1A and NKCC1B, being about 4-times more potent than bumetanide
||DDR inhibitor X
||DDR inhibitor X is a potent discoidin domain receptor (DDR) inhibitor with IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.
||JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM, also shows high potency against a variety of other frequently observed mutants (G1269A, S1206Y, F1174L and C1156Y)
||RO1138452 is a potent, selective antagonist of prostacyclin receptor (IP receptor), inhibits carbaprostacylin-stimulated c-AMP accumulation in human SH-SY5Y neuroblastoma cells with pKb of 8.8
||YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor with inhibitory activity against PAD2 (IC50=0.5-1 uM) and PAD4 (IC50=1-2 uM), inhibits U2OS cancer cell growth with IC50 of 2.5 uM
||Foretinib-Based PROTAC 7
||Foretinib-Based PROTAC 7 is a VHL-recruiting PROTAC that induces the degradation of c-Met in a dose- and time-dependent fashion in MDA-MB-231 cells.
||Gefitinib-based PROTAC 3
||Gefitinib-based PROTAC 3 is a VHL-recruiting PROTAC that induces the degradation of EGFR and EGFR mutants with DC50 of 11.7 nM and 22.3 nM for HCC827 cell (Exon 19 del) and H3255 cell (L858R).
||AGN192836 (AGN 192836) is a potent, selective α2 adrenergic (alpha 2-adrenoceptor) agonist with EC50 of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively
||BAY-320 (BAY320) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 680 nM
||BAY-524 (BAY524) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 450 nM
||GLX351322 (GLX-351322) is a novel potent inhibitor of NADPH oxidase 4 (Nox4), inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells with IC50 of 5 uM
||H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo
||Lipofermata (CB16.2 aka) is a specific fatty acid transport (FATP) inhibitor, blocks human FATP2-mediated fatty acid uptake (IC50=4.84 uM in Caco-2 cells) without impacting other cellular functions
||Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload
||LY500307 (LY-500307, Erteberel, SERBA-1) is a potent, selective Estrogen Receptor β (ERβ) agonist with Ki/EC50 of 0.19/0.66 nM, 12-fold higher affinity than ERα and exhibits 32-fold more functional potency
||ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme ADAM-17, significantly decreases the level of NICD and accumulation of NICD in the nucleus
||EGFR-HER2 Ex20Ins inhibitor 1a
||EGFR-HER2 Ex20Ins inhibitor 1a is a highly potent, broadly effective EGFR and HER2 Exon 20 insertion mutant inhibitor with biochemical IC50 of <0.5 nM (wtEGFR, 100 uM ATP)
||SOD1-Derlin-1 inhibitor 56-59
||SOD1-Derlin-1 inhibitor 56-59 is a cell-permeable, small molecule inhibitor of SOD1-Derlin-1 interaction, target SOD1 DBR and clearly attenuates the interactions of Derlin-1 with 122 types of SOD1mut in the cell-based co-immunoprecipitation assay
||KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity
||OUL35 (NSC39047) is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of 330 nM, displays remarkable selectivity towards ARTD10 over other enzymes in the human protein family
||Tecovirimat (ST-246) is a potent, orally bioavailable, first-in-class inhibitor of orthopoxvirus egress with EC50 of 0.01-0.6 uM against a panel of Orthopoxviruses
||EMD-281014 is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels
||EMD-281014 hydrochloride is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels
||FTBMT is a novel selective GPR52 agonist of GPR52, increases intracellular cAMP levels in CHO cells expressing human, mouse, or rat GPR52, with pEC50 of 7.03, 6.85, and 6.87M, respectively
||IK1 inhibitor PA-6
||IK1 inhibitor PA-6 is an efficient, specific inhibitor of inward rectifier current (IK1), blocks KIR2.x currents of human and mouse with IC50 of 12-15 nM
||JG-231 is an allosteric inhibitor that disrupts the Hsp70-BAG3 interaction (Ki=0.11 uM), inhibits breast cancer cells MCF-7 and MDA-MB-231 with IC50 of 0.12 and 0.25 uM, respectively
||SOS1 activator 17
||SOS1 activator 17 is a small molecule activator of guanine nucleotide exchange factor SOS1 with EC50 of 0.8 uM, modulates RAS signaling in vitro
||GlyT1 inhibitor 46
||GlyT1 inhibitor 46 is a novel potent, selective, orally available inhibitor of glycine transporter-1 (GlyT1) with IC50 of 38 and 21 nM for rat and human GlyT1, respectively
||TCASK10 is a potent, highly specific inhibitor of ASK1 with IC50 of 14 nM, 30-fold selectivity over ASK2 (IC50=510 nM) and no activity against MEKK1, TAK1, IKKβ, ERK1, JNK1, p38α, GSK-3β, PKCθ and B-raf
||QCA570 is a novel, highly potent efficacious BET degrader (PROTAC)
||QCA276 is a novel potent BET proteins inhibitor with IC50/Ki of 10/.3 nM, QCA276 is the BET ligand for PROTAC QCA570
||BET inhibitor CF53
||BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1)
||Omidenepag Isopropyl (OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor
||SR2211 (SR-2211) is a potent, selective RORγ inverse agonist (Ki=105 nM, IC50=320 nM) that potently inhibits production of IL-17 in cells
||MRL-871 (MRL871) is a potent, selective inhibitor of RORγt via allosteric inverse agonism, inhibits coactivator binding with IC50 of 7 nM
||ASS234 (ASS-234) is a multitarget, potent, and CNS permeable inhibitor with IC50 of 5.2, 43, 350 and 460 nM for MAO-1, MAO-B, EeAChE and eqBuChE, respectively.
||IGS-1.76 is a small molecule inhibitor of human NCS-1/Ric8a interaction with affinity of 1.25 uM (hNCS-1)
||RORγt inverse agonist 22
||RORγt inverse agonist 22 is a potent, subtype selective RORγt inverse agonist with binding IC50 of 18 nM, displays >192-fold selectivity over RORα and RORβ
||Desmethyl dabrafenib (GSK2167542, Dabrafenib metabolite M8) is the desmethyl- metabolic byproduct of Dabrafenib, ameliorates developmental pathologies of Kabuki Syndrome in vivo.
||ClpP inhibitor M21
||ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay
||MALT1 paracaspase inhibitor 3
||MALT1 paracaspase inhibitor 3 is a potent, specific, covalent inhibitor of MALT1 paracaspase with Ki of 10 nM, exhibits 10-and 100-fold improved potency in vitro and in vivo compared with Z-VRPR-fmk
||SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes
||UniPR1331 (UniPR-1331) is a selective, orally available antagonist of Eph/ephrin interaction with pIC50 of 5.45, IC50 of 2.9 uM
||Cenupatide is an urokinase plasminogen activator receptor (uPAR) inhibitor for treating disorders associated altered cell migration, such as cancer.
||Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.
||Dersimelagon is a melanocortin receptor agonist.
||Exicorilant (CORT125281, CORT-125281) is a potent, selective glucocorticoid receptor (GR) antagonist, exhibits no cross-reactivity for the PR and AR receptors.
||GR3027 (Golexanolone) is a GABA-A receptor modulating steroid antagonist that selectively antagonizes the enhanced activation of GABAA receptors by neurosteroids such as allopregnanolone and THDOC
||Neluxicapone is a potent, selective inhibitor of catechol-O-methyltransferase (COMT).
||Soticlestat is a potent, selective cholesterol 24-hydroxylase inhibitor.
||Taniborbactam is a novel beta-lactamase inhibitor for the treatment of bacterial infections.
||Tildacerfont is a novel corticotropin releasing factor (CRF) CRF1 receptor antagonist.
||TRPM8 antagonist 14
||TRPM8 antagonist 14 is a potent, selective TRPM8 antagonist with IC50 of 0.2 nM in calcium influx assays, shows no activity on TRPV1.
||PF-06764427 (PF06764427) is a potent, selective M1 muscarinic acetylcholine receptor (mAChR) positive allosteric modulator with EC50 of 55 nM, has no measurable agonist or PAM activity at the M2-M5 receptors at 10 uM.
||VU0453595 (VU453595) is a potent, selective M1 positive allosteric modulator (PAM) with EC50 of 3.2 uM (rM1).
||PF-06827443 (PF06827443) is a potent, orally bioavailable, and CNS-penetrant M1-selective positive allosteric modulator (PAM) with EC50 of 47 nM, shows no activity against M2-M5 at 10 uM.
||KRM-II-81 is a potent, selective α1/α2/α3 GABAA receptors positive allosteric modulator with EC50 of 937 nM for α1β3γ2, negligible efficacy at α4/α5/α6 GABAA receptors.
||HZ-166 (HZ166) is a GABAA receptor subtype-selective benzodiazepine site ligand with preferential activity at α2- and α3-GABA(A) receptors.
||GAT-211 (GAT211) is a selective cannabinoid 1 receptor (CB1R) positive allosteric modulator with pKb of 7.26, Arrestin2 EC50 of 775 nM.
||VU6004256 (VU 6004256) is a highly potent, selective M1 muscarinic acetylcholine receptor (mAChR) positive allosteric modulator with EC50 of 155 nM (mouse M1), significant selectivity over M2-M5 (EC50>30 uM).
||VU0418506 (VU 0418506) is a potent and selective mGlu4 positive allosteric modulator (PAM) with EC50 of 68 nM (hmGlu4).
||GAT-100 (GAT100) is a potent, selective CB1R negative allosteric modulator (NAM) with cAMP EC50 and β-arr EC50 of 174 nM and 2.1 nM, does not exhibit inverse agonism.
||VU0467154 (VU 0467154) is a potent, selective M4 mAChR positive allosteric modulator with EC50 of 17.7 nM.
||D-520 is a potent, multifunctional D2/D3 agonist with Ki of 41.8 /0.35 nM, modulates aggregation of alpha-synuclein (αSN) and reduces toxicity of preformed aggregates of αSN.
||HS94 (DAPK3 inhibitor HS94) is a selective DAPK3 inhibitor with Ki of 126 nM, >20-fold selectivity over Pim kinases.
||HS148 (DAPK3 inhibitor HS148) is a selective DAPK3 inhibitor with Ki of 119 nM, >10-fold selectivity over Pim kinases.
||Wnt-p53 inhibitor compound 2
||Wnt-p53 inhibitor compound 2 is a novel inhibitor targets both Wnt signaling and ATM/p53, potently inhibits Wnt transcription (IC50=11 nM) and p53 transcription (EC50=1.9 nM).
||CFM-4.16 is a CARP-1 functional mimetic (CFM) compound bind with CARP-1, stimulates CARP-1 expression and apoptosis.
||RCM-1 (FOXM1 inhibitor RCM-1) is a nontoxic, small molecule that inhibits FOXM1 activity in vitro and in vivo, inhibits GFP-FOXM1 in U2OS cells with EC50 of 0.72 uM.
||JAK2 inhibitor G5-7
||JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2.
||GPR40 AgoPAM AP5
||GPR40 AgoPAM AP5 is a potent, selective GPR40 AgoPAM (full agonist with positive allosteric modulation) with hIP1 EC50 of 0.8 nM, high selectivity over the GPR120 receptor (EC50>30 uM).
||NBI-59159 (NBI59159) is a potent EAAT3-preferring inhibitor.
||WAY-213613 is a selective GLT-1/EAAT2 inhibitor.
||PF-06885249 (PF06885249) is a potent, direct AMPK activator with EC50 of 7.0 and 27 nM for α1β1γ1 and α2β1γ1, respectively.
||AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM.
||Roxyl-WL is a highly potent and selective inhibitor of IDO1 with IC50 of 1 nM.
||Qstatin is a potent SmcR inhibitor in V. vulnificus. with IC50 of 208.9 nM, shows pan-QS (quorum sensing) inhibitor activity in diverse Vibrio species.
||RB-005 (RB-005) is a potent, selective inhibitor of sphingosine kinase SphK1 (SK1) with IC50 of 3.6 uM, displays 15-fold selectivity over SphK2.
||MID-1 (ChemBridge5655896) is a specific small molecule MG53-IRS-1 interaction disruptor (MID), but not MG53-FAK and-Cav-3 interaction.
||AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.
||MLS6585 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies.
||HX600 (HX-600) is a synthetic agonist of RXR-Nurr1 heterodimer complex, also selectively activate NGFI-B/RXR heterodimers.
||VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator, binds and activates PPARγ (IC50=3.5 uM) and CB2 receptors (pKi=6.69) and antagonizes CB1 receptor (pKi=5.61).
||AF64394 is a potent, selective GPR3 inverse agonist with pIC50 of 7.3, displays >100-fold selectivity over GPR6 and GPR12.
||NFEPP is a novel potent, selective pH-dependent μ-opioid receptor (MOR) agonist with a low pKa, shows significantly lower affinity compared with fentanyl at pH 7.4.
||ASP7657 is a novel, potent, and selective prostaglandin EP4 receptor antagonist and exhibits high affinity for rat and human EP4 receptors with Ki of 6.02 nM and 2.21 nM, respectively.
||S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).
||STING CDN agonist IFM Therapeutics
||STING CDN agonist IFM Therapeutics is a synthetic cyclic dinucleotide (CDN) agonist of STING, stimulates potent immunity against cancer.
||Amgen16 is a highly potent inhibitor of NF-κB inducing Kinase (NIK), example 294 in patent WO 2009158011 A1.
||AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent.
||ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL).
||GSK4027 (GSK 4027, GSK-4027) is a potent, selective, cell-penetrant chemical probe of PCAF/GCN5 bromodomain with pKi of 8.9 for both.
||PF-4778574 (PF4778574) is a brain penetrant, positive allosteric modulator (potentiator) of AMPA receptor with Ki of 85 nM, increases S-AMPA-evoked responses in rat primary cortical neurons with EC50 of 45-919 nM.
||GNE-6468 (GNE6468) is a potent and selective RORc inverse agonist (EC50=2 nM) with >1,000-fold selectivity for RORc over PPARγ.
||APX2009 (APX-2009) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.45 uM for redox EMSA inhibition.
||APX2014 (APX-2014) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.2 uM for redox EMSA inhibition.
||AP14145 (AP-14145) is a potent, selective negative allosteric modulator of KCa2.2 and KCa2.3 with equal potency (IC50=1.1±0.3 uM).
||UoS12258 (UoS-12258) is a selective, positive allosteric modulator of the AMPA receptor with pEC50 of 5.6.
||CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.
||NGI-1 derivative C-19
||NGI-1 derivative C-19 is a specific, small-molecule inhibitor of oligosaccharyltransferase (OST) catalytic subunit STT3B, without effect on STT3A.
||INU-101 (INU101) is a highly potent, selective, orally acitve 11β-HSD1 inhibitor with IC50 of 26.2 nM, 37 nM and 0.6 nM for mice, rats, and human 11β-HSD1, respectively.
||HSD-016 (HSD016) is a potent, selective, and efficacious 11β-HSD1 inhibitor with IC50 of 149 and 530 nM for mouse and human 11β-HSD1, respectively.
||INCB13739 (INCB-13739) is a potent, selective, oral 11βHSD1 inhibitor (IC50=1.1 nM) with high seelctivity over other dehydrogenases, glucocorticoid and mineralocorticoid receptors.
||TAK-071 (TAK071) is a novel potent, selective, low cooperativity (α-value) positive allosteric modulator of muscarinic M1 receptor with inflection point of 2.7 nM in Ca2+ flux assays in CHO-K1 cells.
||MFN2 agonist B-A l
||MFN2 agonist B-A/l is a mall-molecule mimics of the peptide-peptide interface of MFN2, allosterically activates MFN2 and promotes mitochondrial fusion with EC50 of 3 nM.
||NP161 is a potent and selective inhibitor of extracellular TRX (Thioredoxin 1) in vitro with IC50 of 0.54 uM.
||MAI-150 is a peptidomimetic inhibitor of APC-Asef interaction, blocks colorectal cancer migration.
||BAY-8002 is a novel potent, selective, orally available monocarboxylate transporter 1 (MCT1) inhibitor (Kd=7.9 nM), inhibits cellular lactate uptake in DLD-1 cells with IC50 of 8 nM.
||PF-06747711 (PF06747711) is a potent, selective, orally bioavailable RORC2 (RORγt) inverse agonist with IC50 of 4.1 nM.
||VERU-111 is a novel, oral α and β tubulin inhibitor that would be a therapeutic option for hormone sensitive and castrate resistant advanced prostate cancer.
||T1551 is a novel selective PRMT5 inhibitor with IC50 of 34.1 uM, decreases cell viability of A549 cell with IC50 of 5.8 uM (72h).
||LIT-927 (LIT927) is the first selective, locally and orally active CXCL12 neutraligand with Ki of 267 nM for CXCL12-TR binding inhibition.
||JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2.
||KB-141 (KB141) is a potent, selective thyroid hormone receptor TRβ agonist (IC50=1.1 nM), binds to hTRβ with a 14-fold higher affinity than to hTRα.
||PHY34 is a potent autophagy inhibitor with cytotoxic effects by inhibiting autophagy at a late stage (MDA-MB-435 IC50=23 nM, MDA-MB-231 IC50=5.2 nM).
||UAB30 (9cUAB30) is a novel synthetic rexinoid that binds selectively to the retinoid X receptor (RXR) leading to activation of genes involved in induction of differentiation and apoptosis.
||Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia.
||XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM.
||Casein Kinase inhibitor A86
||Casein Kinase inhibitor A86 (CKIα inhibitor A86) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=1-10 nM, CKIα Kd=9.8 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19.
||BTX161 is a thalidomide analog that mediates degradation of CKIα better than lenalidomide in human AML cells and activates DDR and p53, while stabilizing the p53 antagonist MDM2.
||Amt-87 is a HIV latency-reversal agent that reactivates latent HIV at the transcriptional level, promotes phosphorylation of CDK9 T-loop at Thr186.
||iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.
||IITZ-01 (Autophagy inhibitor IITZ-01) is a novel potent lysosomotropic autophagy inhibitor, exhibits >10-fold potent autophagy inhibition along with 12- to 20-fold better cytotoxic action than Chloroquine.
||TP0438836 is a potent, low-absorbable sodium-dependent SGLT1 inhibitor with IC50 of 28 nM, and also inhibits SGLT2 with IC50 of 7 nM.
||GNE-8505 is a dual leucine zipper kinase inhibitor with Ki of 4 nM.
||EML-405 (EML405) is a small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 14 uM.
||NVS-ZP7-4 is the first reported chemical tool to probe the impact of modulating ER zinc levels.
||Compound 69 (PFKFB3 inhibitor) is a potent PFKFB3 inhibitor with IC50 of 14 nM and shows inhibition in HCT116 cells with IC50 of 0.49 μM.
||MIDD0301 is an allosteric GABAAR agonist with binding affinity of 72 nM.
||(S)-DO271 is an inactive control of DO264.
||EML741 is a novel chemotype of histone lysine methyltransferase EHMT1/2 (GLP/G9a) inhibitor with IC50 23 nM.
||JNJ-64326067 is a potent and selective binder to aggregated tau and would be a new promising tau positron emission tomography (PET) imaging tracer.
||JNJ4796 is an orally active inhibitor of influenza A HA and neutralizes influenza A group 1 viruses by inhibiting hemagglutinin-mediated fusion.
||NLX-204 is a novel high selective 5-HT1A receptor-biased agonist with pKi of 10.19.
||NV-5138 is the first selective Brain mTORC1 activator and binds to Sestrin2 with Kd of 1.5 µM.
||GSK8612 is a highly potent and selective inhibitor for TBK1 (Tank-binding Kinase-1) with pKd of 8.0.
||VU6019278 is a potent mGlu7 NAM inhibitor with IC50 of 501 nM and shows favorable plasma protein binding, low predicted hepatic clearance and high CNS penetration.
||NPD2381 is a novel and selective cancer-stemness inhibitor that targets mitochondrial metabolism.
||DS21360717 is a FER tyrosine kinase inhibitor with IC50 of 0.49 nM.
||RK-287107 is a potent TNKS/TNKS2 inhibitor with IC50 of 14.3 nM/10.6 nM and shows >7,000-fold selectivity against the PARP1.
||YKL-5-124 is a potent, selective and covalent CDK7 inhibitor with IC50 of 9.7 nM, which shows no inhibition to CDK12/CDK13.
||ML390 exerts its potent differentiation effect on multiple leukemia models.
||CDK2 is a member of the eukaryotic S/T protein kinase family and its function is to catalyze the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S0/T0) in a protein substrate.